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Session 1: Opening/From History to Genetics
KL1. Atopic Dermatitis and Dermatological Doctrines : A Historical Approach
Daniel Wallach, M.D.
President of the European Society for the History of Dermatology and Venereology. Hoˆpital
Tarnier-Cochin, 89 rue d’Assas, 75006-Paris–France
dwallach@noos.fr http://www.bium.univ-paris5.fr/sfhd/
Atopic symptoms have been identified since Antiquity but there is still a lack of consensus
about an accurate definition of the dermatological component of atopy. In this lecture we will
propose that the definition and description of ‘‘atopic dermatitis’’ relies on the dominant
medical doctrine. Before 1800, Hippocratic humoralism dominated the medical thought. Skin
was considered as an excretory organ and oozing was perceived as a beneficial event. A
therapeutic intervention leading to the termination of oozing could have deleterious
consequences. Nevertheless, a disorder characterized by an itchy, predominantly cephalic
rash in infants was readily identified, and described under various headings. Around 1800,
Willan, Bateman and their followers started to look at the elementary lesions of skin disorders
and proposed to classify dermatoses accordingly. This clinical approach was successful for
diseases such as psoriasis, which could be rather well defined by squamous lesions. But a
disorder where one can find papules, vesicles, pustules was not easily denominated. At the
end of the nineteenth century, a wider attention for the symptom pruritus and for whole
patient’s clinical presentation led to the description of ‘‘diathetic prurigo’’. At the same time,
pediatricians favored a digestive approach of infantile eruptions and the etiology of infantile
eczema was looked for in dietary considerations. Shortly after the discovery of anaphylaxis
and allergy, the positivity of skin and blood tests for proteins was discovered in children with
eczema. It was thus felt that this was an important pathophysiological clue. In 1933, Wise and
Sulzberger named atopic dermatitis and proposed the first criteria, including clinical data and
the positivity of allergy tests. Confusion recently arouse when it became obvious that many
patients with so-called atopic dermatitis do not have allergy stigmata.
In 2005, there are at least three doctrines allowing an approach of atopic dermatitis’
definition:
1 – according to the allergological doctrine, AD is the cutaneous component of the atopic
disease, an immunological disorder with hyper IgE and other well established immune
abnormalities. Inside this doctrine, variants put the stress on milk, on other foods, on gut
flora, . . .
2 – according to the dermatological doctrine, AD is an eczema, predominating in young
children, with a genetic predisposition and characteristic clinical features, well described
in 1980 by J Hanifin and G Rajka. The inflammatory symptoms are characteristically
associated with epidermal abnormalities.
3 – according to the public health doctrine, AD is a chronic itch starting in infancy.
Therapeutic choices follow medical doctrines. Humoralist physicians did not want to
interrupt the oozing. Allergologists favor hyposensitizations or avoidance regimens. Dermatol-
ogists treat the skin with anti-inflammatory topicals. They must face corticophobia, which is
frequent in the lay public as well as among health professionals.
Scientific meetings such as the Rajka Symposias are needed to allow encounters of
scientists defending different doctrines. In our opinion, theoretical discussions are interesting to
understand the true meaning of medical approaches and to select the options the more likely to
directly benefit patients.
KL2. Genetics and Epigenetics of Atopic Dermatitis
WOCM Cookson
The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, United
Kingdom
Atopic Dermatitis is strongly familial and has a genetic as well as an environmental basis.
Progress in understanding the genetics of AD is likely to accelerate in the post-genome era.
Genetic Mapping studies have identified several chromosomal regions that contain genes
predisposing to AD. Four of these regions correspond to known psoriasis loci, and one region
in addition shows genetic linkage to psoriasis susceptibility. Detailed mapping of these loci is
being carried out in several centres. Our group, in addition, has been carrying out gene
expression analyses of keratinocytes during differentiation and the response to inflammatory
stimuli. The results from these studies reveal much that is new about keratinocyte biology, as
well as indicating key candidate genes for genetic mapping and association.
IC1. World Wide Variation of Risk Factors in Infants with Atopic Dermatitis
Thomas Diepgen on behalf of the EPAAC study group
University Hospital Heidelberg, Dept. of Social Medicine, Occupational and Environmental
Dermatology, Germany
Atopic dermatitis (AD) is a chronically relapsing, inflammatory skin disease with an early onset
during infancy and a high impact on quality of life and socio-economic burden. Development
of allergic diseases may be determined by some key factors in very early life. In some children
there is also a progression from food allergy and atopic dermatitis to asthma. Early
sensitisation to allergens is thought to be a key factor in the progression of the disease, from
food allergy and atopic dermatitis to asthma as well as to persistent AD in later life. However,
good epidemiological data about risk factors from different countries are missing. In our study
children aged 1–2 years with active dermatitis and a family history of allergy were investigated
in 12 countries (Australia, Austria, Belgium, Czech Republic, Germany, Spain, France, UK,
Italy, The Netherlands, Poland, South Africa). Data were obtained on 2184 AD children with a
mean age of 18 months; 57% were boys. The mean SCORAD was 33; 68% of the children
had moderate-severe dermatitis (SCORAD425). Two-thirds of the children were atopic (at
least one specific IgE, or total IgE430kU/l) with high variations among the countries. It can be
clearly demonstrated that country specific exposures are significantly associated with early
sensitisations. These findings are important with respect to prevention measures. In contrast
to the exposure to cat only the exposure to dog was negatively associated with the
sensitisation rate in AD infants and the exposure to cat and dog is associated with a lower
sensitisation risk against cat allergen. Exposure to cat and/or dog did not increase the
severity of AD in this age group. These findings might be important for guiding prevention
measures in families with AD children. Additionally, the study gave new data about
vaccination and AD. Common vaccinations in early childhood are mostly not positively
associated with an increased risk of allergic sensitization or with more severe AD. In general,
parents of children predisposed for atopy should be encouraged to provide them effective
vaccination against potentially harmful diseases.
OC1. Microarray Analysis of Atopic Skin Lesions
H Sugiura, T Ebise, T Tazawa, K Tanaka, Y Sugiura, M Uehara, K Kikuchi, T Kimura
Dept of Dermatology, Shiga Univ of Medical Science, Genomic Sci Labo Res Div Sumitomo
Pharmaceut Co., Ltd, 2nd Exp Ser Div Bureau of Int Coop International Medical Center of
Japan
sugiurah@belle.shiga-med.ac.jp
Background: Pathogenesis of atopic dermatitis has been attributed primarily to IgE
elevation, and the disease has been classified as an atopic disease similar to allergic rhinitis
or bronchial asthma. However, there have been few reports about the skin-specific
abnormality on atopic dermatitis. Present study was designed to scoop gene expression
which are specific to active atopic skin lesions.
Patients/Methods: We analyzed 23,000 genes in 17 atopic lesions and 4 normal controls
using Affymetrix oligonucleotide arrays.
Results: Four of the 10 genes with the highest change in expression, S100A8 (32 up-
regulated) and S100A7 (6.0 up-regulated), and loricrin (6.5 down-regulated) and filaggrin (5.1
down-regulated), were epidermal differentiation genes located in 1q21, a locus previously
reported to have a genetic linkage with atopic dermatitis. Keratin 6 (locus12q13) and keratin
16 (locus17q12-q21) were up-regulated, whereas keratin 5, 14, 1, and 10 were not.
Furthermore, the elafin (20q12-q13) and human b defensin 2 (8p23.1-p22) genes, both
epithelial host defense proteins (6, 7), were not over-expressed in atopic skin lesions.
Conclusions: Our results, showing down-regulation of the cornified envelope genes and up-
regulation of the alternative keratinization pathway, are the first to suggest abnormal
epidermal differentiation and defective defenses as key abnormalities in atopic dermatitis.
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OC2. Gene-Expression Proﬁling of Lesional and Atopy Patched Tested Skin in Patients
with Atopic Dermatitis using cDNA microarrays
Sa¨a¨f A4, Bradley M1,2, Tengvall-Linder M3, Chang HY4, Wahlgren C-F1, Scheynius A3,
Nordenskjo¨ld M2, Brown P.O4,5
1Departments of Molecular Medicine, 2Dermatology, 3Immunology, 4Karolinska Institutet,
Karolinska University Hospital, Stockholm, Sweden; Departments of Biochemistry, 5Howard
Hughes Medical Institute, Stanford University School of Medicine and Dermatology,
Stanford University School of Medicine, Stanford, California, USA
Maria.Bradley@cmm.ki.se
We have used human cDNA microarrays to advance the understanding of Atopic Dermatitis
(AD). The work presented here provides a detailed molecular picture of the programmed
responses of the human genome to the pathological condition of AD. In addition we have
performed immuno- histochemistry (IHC) studies to assess the generality of the results
generated by the microarrays.
Skin biopsy samples were taken from two groups of individuals: AD patients sensitized to
the opportunistic yeast Malassezia sympodialis and non-atopic healthy individuals (controls).
Three skin biopsies were taken from each individual, i.e. lesional skin from AD patients (or
healthy skin from control individuals), and M. sympodialis and PBS patch-tested skin. The
cDNA microarrays used were produced at the Stanford functional genomics facility (http://
www.microarray.org/sfgf/jsp/home.jsp), and contained  42.000 cDNA. Data were analyzed
by different methods; both unsupervised (hierarchal clustering) and supervised methods
(using SAM, Significan Analysis of Microarray and gene-lists).
We here present a picture of approximately 1,500 genes differently expressed between
healthy control individuals and lesional skin from AD patients (who often showed the same
expression pattern as M. sympodialis tested skin). A selection of these genes is described in
more details in the context of their biological function and possible role in the pathogenesis of
AD.
(I). Immune response; Increased expression levels were detected in the lesional and M.
sympodialis tested skin of genes encoding the interleukin-4 receptor (IL-4R), interleukin-6
receptor (IL-6R) and the IgE receptor, gamma subunit (FCER1G) and genes encoding
chemokines such as CCL2, CXCL1, CXCL3, CXCL4 and CXCL9. We observed a four-fold
difference between involved and uninvolved skin of AD patients in the expression levels of
SOCS-3. This result has been confirmed with IHC studies and further investigations of the
SOCS-3 gene are ongoing.
(II). Barrier function; We identified a number of genes with lower expression levels in lesional
skin compared to uninvolved skin of AD patients and control individuals. This included
genes encoding known components of epithelial cell-to-cell junctions and enzymes
involved in lipid metabolism.
(III). Defense mechanisms of the skin; It has previously been reported that antimicrobial
peptides are produced at lower levels in the skin of AD patients compared with psoriasis.
We identified a gene involved in biosynthesis of antimicrobial peptides (LANCL1) with
decreased expression levels in lesional skin as compared to uninvolved skin from AD
patients and healthy controls. Other genes expressed at a lower level in lesions were
mucin 1 (MUC1; a glycoprotein with a role in protecting many epithelial surfaces) and
secretory leucoprotease inhibitor (SLIP; with antibacterial, antiviral, and anti-inflammatory
functions).
(IV). Signaling pathways; Genes encoding members of the epidermal growth factor receptor
(EGFR) protein family showed decreased expression levels in lesional skin as compared to
non-involved skin. The EGFR signaling pathway plays a key role in the regulation of cell
proliferation, survival and differentiation.
In summary, we here report that lesional skin and induced eczema (i.e. M. sympodialis
tested skin) share very similar gene-expression patterns. This initial study provides information
about potential new candidate genes possibly involved in the pathology of atopic dermatitis,
which could help explain abnormalities in AD skin.
OC3. Positional Cloning of a Susceptibility Gene for Childhood Eczema from Chromo-
some 1q21
Edser P, Street T, Taylor M, Broxholme J, Harper JI, Cookson WOC, Moffatt MF
The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK and The
Institute for Child Health, Great Ormond Street, London
miriam@well.ox.ac.uk
Eczema (atopic dermatitis, AD) is strongly familial and has a genetic basis. In order to identify
genes predisposing to AD we have previously carried out a whole genome screen and have
identified regions of linkage on chromosomes 1q21, 17q25 and 20p. The chromosome 1q21
locus overlies the epidermal differentiation complex (EDC). The genes of the EDC are
expressed late during maturation of epidermal cells. A systematic search identified 189 single
nucleotide polymorphisms (SNPs) in 54 genes from the EDC, including 35 coding for amino-
acid changes. One hundred and eleven of these were typed in a panel of 150 nuclear families
recruited through a child with severe eczema from clinics at Great Ormond Street Hospital
(The ECZ1 panel). Forty-one SNPs showing potential association with AD by transmission/
disequilibrium tests (Po0.01) were carried through for typing on an additional panel of 278
families containing 470 sibling pairs (the MRC-E panel). One SNP showed strong evidence for
replication of association to AD and to asthma (T60:NT30, P¼ 0.0002 and T53:NT14,
P¼ 0.000002 respectively in the MRC-E panel). It and other associated SNPs were carried on
a susceptibility haplotype that was highly significantly associated with eczema (T95: NT50,
P¼ 0.0002 in the combined panels). The haplotype contains two genes that are over-
expressed in skin biopsies of eczematous lesions. These have a potential role in modifying
the response of the skin to infections.
OC4. The Links Between Gut Worms, Malaria, and Atopic Dermatitis: A Study in Rural
Vietnam
Carsten Flohr
Centre for Evidence-Based Dermatology, University of Nottingham, Nottingham, UK
flohr@dng.vnn.vn
Background: Atopic dermatitis is becoming increasingly frequent in urban centres of
developing nations. Developing countries such as Vietnam therefore appear ideal locations
for the study of potential aetiological factors, with stark lifestyle differences between urban
and rural areas. Various epidemiological studies have suggested that endoparasite exposure
(e.g. to hookworm) may be an important factor for the urban/rural gradient of allergic disease.
It is, however, possible that some of this effect is due to confounding or reverse causality, ie
that atopics have an immune system that reduces parasite burden. Only an intervention study
will be able to differentiate between causality, confounding and reverse causality.
Study design: Among 1824 primary and secondary schoolchildren in rural Vietnam, we are
therefore conducting 1) a cross-sectional baseline survey to assess gut parasite and atopic
dermatitis and asthma prevalences, followed by 2) a randomised, double blind, placebo-
controlled trial of three-monthly gut parasite eradication to study the effect of loss of gut
parasite infection on skin prick test positivity and clinical expression of atopic dermatitis and
asthma.
Main outcome measures: At baseline, we use the International Study of Asthma and Allergies
in Childhood questionnaire to gather information on allergic disease symptoms and lifestyle
factors. All participants are also physically examined for atopic dermatitis, using the UK
diagnostic criteria, and skin prick tested to Dermatophagoides pteronyssinus, Dermatopha-
goides farinae, and American cockroach. Gut worm infection is diagnosed qualitatively and
quantitatively on stool sampling, using the McMaster method. Malaria status is determined
with thin and thick blood films. In addition, a randomly selected subgroup of 200 secondary
schoolchildren has donated venous blood for cytokine profiles, including IL-4, IL-5, IL-10,
TNF-alpha, and IFN-gamma.
Following the initial baseline survey, all participants are randomised to either Mebendazole
or placebo treatment, stratified by school, and given four times every three months. All
baseline measurements are to be repeated at 8 weeks and 12 months into the study to
examine whether phased gut parasite eradication promotes an increase in the clinical
expression of atopic dermatitis and asthma and skin prick test positivity, and whether this
also results in measurable changes in the host cytokine profile to explain pre and post
parasite eradication differences in allergic disease prevalence.
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P1. Epidemiological Characteristics of Atopic Dermatitis in India
A J Kanwar
Dept. of Dermatology, PGIMER, Chandigarh, India
kanwaraj@hotmail.com
Atopic dermatitis (AD) is a common inflammatory skin disease, encountered in the pediatric
age group. The prevalence of AD appears to have increased over the past three decades in
western countries. Most of the epidemiological studies on AD are based on western
population, with little published information in Asians and people from developing countries.
In our earlier reports, we have studied the clinical profile of AD including major and minor
criteria. We retrospectively analysed the pediatric dermatology clinic records to study
epidemiological characteristics of the disease over the last 15 years. Diagnosis of AD was
based on diagnostic criteria of Hanifin and Rajka. Based on body surface area involvement,
disease was considered to be mild (o20%), moderate (20–50%) and severe (450% body
area involvement).
Of the total 271,839 new patients seen during this period in the Dermatology outpatient
department, 1542 children had AD making an incidence of 0.56%. Out of 3521 total number
of new patients seen in the pediatric dermatology clinic during the same period, AD
comprised 43.8% of the pediatric dermatoses. Of the 1542 patients, 435 (28.2%) were infants
(up to 1 year), of whom 295 (67.8%) were boys and 140 (32.2%) were girls with a male:female
ratio of 2.07:1. Mean age at onset of the disease was 3.9 months and mean duration of
disease was 3.1 months. 96 (22.0%) infants were from a rural background and 339 (78%)
lived in urban area. A personal and family history of atopy was noted in 4 (0.91%) and 168
(38.6%) infants respectively. No patient had any suspected drug or food allergy.
Of the 1089 children with AD, 684 (62.8%) were boys and 405 (37.2%) were girls, with male:
female ratio of 1.3:1. Mean age of onset and mean duration of disease was 3.6 years and 1.2
years respectively. 284 (26.0%) patients were from a rural background and 805 (73.9%) were
from an urban area. Of these children 171 (15.7%) had a personal history of atopy, 467
(42.9%) had a family history of atopy and 85 (7.8%) had both personal and family history of
atopy. Of the total 1542 patients, 1390 (90.1%) had mild disease, 121 (7.8%) had moderate
and only 31 (3.2%) children had severe disease. Atopic dermatitis therefore appears to be a
common problem with significant morbidity in developed nations but relatively of low
prevalence and less severity in developing world. However, prevalence of AD in developing
countries may increase as traditional lifestyle are eroded by increasing adaptation to the living
patterns exhibited by industrialized societies.
P2. Worldwide Changes in the Prevalence if Eczema Symptoms
Hywel Williams, Alistair Stewart, Erika von Mutius, William Cookson, Ross Anderson and
the ISAAC study team
University of Nottingham,
UK hywel.williams@nottingham.ac.uk
Objective: We sought to determine if the prevalence of atopic eczema symptoms have
increased worldwide.
Methods: We studied children (n¼ 298,080) aged 13–14 years in 104 centres from 55
countries around the world, and children aged 6–7 years (n¼185,891) from 64 centres in 36
countries who participated in successive cross sectional prevalence surveys. On average, the
surveys were conducted 7 years apart in the same study centres using validated and
translated questionnaires (Phase 1 and III of the International Study of Asthma and Allergies in
Childhood). Children with a positive response to an itchy relapsing skin rash in the last 12
months that had affected the skin creases were considered to have eczema, and those with
symptoms resulting in sleep disturbance for 1 or more nights per week were considered to
have severe eczema.
Results: Changes in prevalence per year (weighted by the standard error and adjusting for
clustering effects) over the 7 year period were generally small. Many of the centres previously
showing the highest prevalences such as UK and New Zealand now show a levelling off or
decrease in prevalence. Similar patterns are seen for those with severe eczema, suggesting
that differential reporting of mild disease is unlikely to account for the observed changes. The
pattern elsewhere is mixed, with many formally low prevalence countries experiencing
substantial increases in eczema symptoms.
Interpretation: Our results suggest that the epidemic of eczema may be levelling off or even
reducing in some countries with previously high prevalence rates. The study has also
highlighted other areas of the world where an increase in eczema might become the focus of
primary and secondary prevention programmes. The changing prevalence of eczema
symptoms needs to be confirmed in other studies with objective disease markers in order to
exclude changes in the use of the language used to describe eczema symptoms over time.
The fact that measurable changes in symptoms occurred over such a short time suggest that
environmental factors are important in determining eczema expression, and that a threshold
effect may be operating whereby a number of susceptibles develop disease until a plateau of
saturation occurs.
Session 2: Maturation of the Immune System
KL3. Perinatal Maturation of the Immune System: Implications for the Aetiology and
Pathogenesis of Atopic Dermatitis and Related Diseases
Patrick G. Holt
Telethon Institute for Child Health Research, Perth, Western Australia
During fetal life, the developing immune system is shielded from the antigenically hostile
external environment, and the major challenge to homeostasis is regulation of potential
fetomaternal immunological interactions which pose a threat to placental integrity. The
mechanisms selected via evolution for this purpose, centering upon attenuation of fetal
adaptive immune capacity and attendant Th2 polarisation, carry over into the immediate
postnatal period, and contribute to risk for a number of immunoinflammatory and infectious
diseases. Atopy represents an archetypal example of a disease in which risk for disease
development is closely related to immune status at or around the time of birth. Accumulating
evidence suggests that the kinetics of postnatal maturation of immune function is extremely
heterogeneous with the human population, in particular maturation of Th1 function which is
differentially attenuated during fetal life. Moreover, genetic risk for atopy and associated
diseases appears inversely related to the kinetics of this maturation process, high risk being
strongly associated with delayed kinetics. A series of mechanisms contribute to this risk,
including those directly associated with regulation of expression of individual Th1 genes such
as IFNg, and those associated with the efficiency of recognition and transduction of the
microbial derived signals from the postnatal environment (notably genetic variations in TLR
function) which drive Th1 maturation. Additional developmental variations recently docu-
mented within the Eosinophil compartment also contribute to this process. Accumulating
evidence also suggests that the developmental deficiency in Th1 function in high risk children
is in many cases transient, and is followed in a significant number of cases by
hyperresponsiveness in both the Th1 and Th2 compartments. This finding has important
theoretical implications in relation to drug design, as it implies that the same Th1 cytokines
which provide negative feedback to protect against initial allergic sensitisation have the
potential to contribute to atopy pathogenesis once the disease is established. This concept is
already established in the adult atopic dermatitis literature, and data will be presented on its
relevance to the pathogenesis of allergic respiratory diseases in children.
KL4. Gut Microbiota and Atopic Dermatitis
Erika Isolauri
Department of Pediatrics, Turku University Central Hospital, 20520 Turku, Finland
Atopic dermatitis is considered to result from an interplay between susceptibility genes,
impaired barrier functions of the skin and the gut, aberrant gut microbiota, immunological
dysregulation, together with bacterial and viral infections and other environmental factors.
The hygiene hypothesis conceives the increase in the prevalence of atopic disease to be
related to reduced exposure to microbes at an early age. The earliest and most massive
source of microbial exposure is associated with the establishment of the gut microbiota.
The importance of the immunoregulatory potential of gut microbiota is emphasized in the
recent demonstration of cross-talk between the innate and the adaptive immune system. Gut
microbiota provide maturational signals for the gut-associated lymphoid tissue, particularly
for the IgA plasma cells, conferring the first line of host immunological defence. Abundant IgA
antibody production at mucosal surfaces contributes to the intestinal barrier function by
binding to and excluding antigens. Maturation of dendritic cells carrying commensals and
subsequent secretion of cytokines and chemokines then influence the polarization of T helper
cells and thereby the adaptive immune responses, ensuring a local IgA response. This type of
immune response has been suggested to prevent commensals from breaching the gut
mucosal barrier, while pathogenic bacteria preferably destroy it.
Probiotics are live microbial food supplements or components of bacteria which have been
demonstrated to have beneficial effects on human health. The probiotic effects in atopic
eczema have been attributed to restoration to normal of increased intestinal permeability and
unbalanced gut microecology, improvement of the intestine’s immunological barrier
functions, including the production of anti-inflammatory IL-10 and TGF-beta, and reduced
generation of proinflammatory cytokines characteristic of local and systemic allergic
inflammation.
Recent clinical studies have demonstrated a significant improvement in the clinical course
of atopic eczema in infants and children given probiotic-supplemented elimination diet, and in
parallel, markers of intestinal and systemic allergic inflammation decreased significantly.
Moreover, probiotics administered pre- and postnatally for 6 months to children at high risk of
atopic diseases, succeeded to reduce significantly the prevalence of atopic eczema as
compared with that in infants receiving placebo.
Diet is always a combination of many foods and nutrients – their interactions may be more
crucial than is currently understood. Therefore, rigorous scientific effort is required to
elucidate how the dietary context interacts with probiotic supplementation on the complex
cascade of immunological mechanisms in atopic disease.
1. Isolauri E, Rautava S, Kallioma¨ki M, Kirjavainen P, Salminen S. Role of probiotics in food
hypersensitivity. Curr Opin Immunol Clin Allergol 2002;2:263–71.
2. Rautava S, Kallioma¨ki M, Isolauri E. New therapeutic strategy for combating the increasing
burden of allergic disease: probiotics. J Allergy Clin Immunol 2005, in press.
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OC5. Numerical and Functional Abnormality of Circulating Plasmacytoid DC in Atopic
Dermatitis
Hideo Hashizume, Takahiro Horibe, Natsuho Ito, Taisuke Ito, Masahiro Takigawa
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
hihashiz@hama-med.ac.jp
Atopic dermatitis (AD) is a pruritic, chronically relapsing skin disease in which Th2 cells play a
crucial role in cutaneous and extracutaneous immune reactions. In humans, CD11cþCD123-
myeloid dendritic cells (mDC) and CD11c-CD123þplasmacytoid DC (pDC) orchestrate the
decision-making process in innate and acquired immunity. Since the number and function of
these blood DC subsets reportedly reflect the host immune status, we studied the involvement of
the DC subsets in the pathogenesis of AD. Patients with AD had an increased pDC number in the
peripheral blood with correlation to AD-relevant immune parameters including the total serum
IgE level and the ratio of interferon-gamma (IFN-g)-producing blood cells/interleukin-4 (IL-4)-
producing blood cells as well as the disease severity estimated by SCORAD, suggesting pDC
play a critical role for AD pathogenesis. In skin lesions, pDC infiltration was in close association
with blood vessels expressing peripheral neural addressins. In vitro allogeneic stimulation of
naı¨ve CD4þT cells with normal DC showed that the ability of mDC for IFN-g-producing cell
induction was superior to pDC. On the other hand, atopic DC promoted IFN-g-producing cell
differentiation comparable to normal mDC. Although pDC in both AD and normal subjects
promoted differentiation of naı¨ve CD4þTcells into CD4þCD25þCTLA-4þFoxp3þTcells with
regulatory function to T cells which represent peripheral regulatory T cells (Treg), these cells
induced by atopic, but not normal, pDC had the ability to produce high amounts of IFN-g and IL-
5. Taken together, atopic pDC have numerical and functional abnormality compared with normal
pDC. In normal subjects pDC may migrate into inflammatory sites and promote Th2- and
regulatory T cell-differentiation for dampening inflammatory responses. However, atopic pDC
may promote Th1or Treg with high potential for IFN-g and IL-5 production, and thus protracting
Th1-type and/or eosinophilic inflammation via Th1 cell activation and eosinophil trafficking on
site in AD.
OC6. The Severity of Atopic Dermatitis Correlates to Thymic Function
Helle Just1, Mette Deleuran1, Christian Vestergaard1, Bent Deleuran2 and Kristian Thestrup-
Pedersen1
(1). Department of Dermatology, Aarhus University Hospital and (2). Department of
Rheumatology, Aarhus University Hospital and Institute of Medical Microbiology and
Immunology, Aarhus University, Denmark
helle.just@ki.au.dk
We have evaluated thymic function in relation to atopic dermitatis. Fluctuations in thymic
output in patients with atopic dermatitis were measured by T-cell receptor excision circles
(TREC) in peripheral blood CD4þ and CD8þT-cells over a time period. TREC is an episomal
DNA circle produced during T-cell receptor rearrangement and is used as a marker for recent
thymic emigrants.
A group of 10 patients with atopic dermatitis were observed over a period of six months.
Each month the patients were clinically scored with SCORAD and blood samples were
obtained. To investigate the variance in TREC content in healthy individuals, a group of seven
healthy persons were observed over a period of four months.
Over time, normal healthy volunteers showed very little change in their TREC, supporting
that their thymus is working at a constant level. This is in contrast to atopic dermatitis where,
over a time period of 6 months, we observed a large variation in the amount of TREC in
lymphocytes. This variation was observed in both the CD4þ and CD8þT-cell subpopulation.
In comparison to healthy controls this variation was significant (P¼ 0,022 and P¼ 0,008 for
CD4 and CD8 respectively).
Examining the individual components of SCORAD, TREC in both the CD4þ and CD8þT-cell
subpopulation was reversely correlated both with intensity (CD4þ r¼0,27, p¼ 0,045 and
CD8þ r¼0,35, P¼ 0,010) and extent (CD4þ r¼0,34, p¼0,008 and CD8þ r¼0,40 ,
P¼0,003), whereas the subjective symptoms of itching and sleep loss did not show any correlation.
This investigation supports a connection between thymus function and AD disease, and suggests
that atopic dermatitis patients seems to have an increased emission of recent thymic emigrants
during disease flare-up, supporting our hypothesis that atopic dermatitis is associated with altered
thymic emission.
OC7. Probiotics Provide Clinical Beneﬁt in Moderate and Severe Atopic Dermatitis: A
Randomised Controlled Trial
Stephanie Weston1, Janet A Dunstan1, Jasmine Roper1, Liza Breckler1, Anne Halbert2,
Peter Richmond1, and Susan L Prescott1
(1) Paediatrics and Child Health Research, University of Western Australia (2) Princess
Margaret Hospital for Children, Perth, Western Australia
westons@ausdoctors.net
Introduction: The incidence of atopic dermatitis (AD) has increased dramatically in recent
years. The resulting greater morbidity has highlighted the need for novel strategies to reduce
the burden of disease. Probiotic supplements may provide protection from allergic disease,
and improve the symptoms of infants with mild AD, but there is little data on the effects of
probiotics in young children with more severe disease. The rationale for use of probiotic
bacterial products as a therapeutic option in AD has been based on the well-recognised
effects of bacteria on cellular immune responses.
Objective: To investigate the effects of probiotics on moderate or severe atopic dermatitis
(modified SCORAD greater than 25) in young children (6-18 months of age) in a randomised,
placebo controlled, double blind trial. Both clinical and immunological outcomes were
assessed.
Methods: Fifty six children aged 6-18 months with moderate or severe atopic dermatitis were
randomised to supplementation with probiotic (3x109 L fermentum PCCt, [VRI BioMedical]),
or equivalent volume of placebo, twice daily for eight weeks. A final assessment at sixteen
weeks was performed (8 weeks after end of intervention). Severity and extent of AD were
measured by the SCORAD index at week 0, week 8 and week 16. Peripheral blood
mononuclear cells were stimulated with heat killed L fermentum (HKLB). Cytokines (IL-5,
IL13, IL 10, IFNgamma, TNFalpha) were measured in the supernatants.
Results: The reduction in SCORAD index over time was significant in the probiotic group
(p¼ 0.03) but not the placebo group. Significantly more children receiving probiotics (n¼24,
92%) had a SCORAD index that was better than baseline at week 16 compared with the
placebo group (n¼ 17, 63%) (p¼ 0.01). At the completion of the study more children in the
probiotic group had mild AD (n¼ 14, 54%) compared to placebo (n¼ 8, 30%). TNFalpha
responses to HKLB were significantly higher in the probiotic group at week 8 (p¼ 0.022)
compared to placebo. Of note no other cytokine responses were significantly affected.
Conclusion: Supplementation with probiotic Lactobacillus fermentum PCCt is beneficial in
improving the extent and severity of atopic dermatitis in young children with moderate or
severe disease, with persisting clinical benefits 2 months after completion of supplementa-
tion. This study demonstrates that exposure to L fermentum PCCt in the gut has an effect on
systemic TNFalpha responses. The effects of bacterial products on underlying immune
responses require further investigation.
OC8. Involvement of Innate Conditioning of Antigen Presenting Cells by Staphylococcus
Aureus Toxin B in Immune Response of Atopic Dermatitis Patients
Marie Mandron1, Marie-Franc¸oise Aries2, Franck Boralevi3, Marie Charveron2, Alain Taı¨eb3
and Christian Davrinche1
(1) INSERM U 563, CHU Purpan, Toulouse, France (2) Centre de Recherche P. Fabre
CERPER, Toulouse, France (3) Service de dermatologie, Hoˆpital Saint-Andre´, Bordeaux,
France
marie.mandron@toulouse.inserm.fr
Atopic dermatitis (AD) is dominated by the development of specific TH2 responses after
exposure of the skin to environmental antigens. This immune deviation may reflect alterations
in innate immune mechanisms. Recently, it has become clear that the development of TH1 or
TH2 subsets is strongly influenced by factors produced by antigen presenting cells (APCs),
thus representing a link between innate and adaptive immunity.
Toll-like receptors (TLRs) are members of pattern recognition receptors family on APCs that
are activated by specific microbial components and some host molecules. They constitute
the first line of defence against many pathogens and play a crucial role in innate immunity.
Furthermore, TLRs were recently demonstrated to take part in the development of adaptive
immune responses through activation of APCs.
We showed in a previous study that Staphylococcal aureus enterotoxin B (SEB) could
induce activation of monocytes-derived dendritic cells (DCs) through toll like receptor 2
signalling and that SEB-pulsed DCs induced priming of naı¨ve T cells and their commitment
into TH2.
To clarify whether APCs from AD patients could play a role in TH2 cell polarization, we
compared the expression of surface markers and cytokine production by monocytes of 30 AD
patients (15 adults and 15 children) with those of 15 healthy controls, after stimulation with
either LPS or SEB.
First, we observed that contrary to normal subjects atopic dermatitis patients were not able
to further modulate TLR 2 and TLR 4 expression after in vitro exposition to SEB. Accordingly,
cells seemed to be blocked in an activated stage with in addition no modulation of HLA-DR
and CD54 expression. This feature was supported by secretion of large amounts of
inflammatory cytokines (IL-6, IL-10, TNF-a) even in the absence of stimulation. Then, we
observed that atopic monocytes did not produce bioactive IL-12 (IL-12p70) in response to
LPS contrary to normal subjects but that secretion could persist in atopic children. These
findings demonstrate that cytokine responses changed markedly between normal and atopic
persons and provide further evidence of a close relationship between Th2 skewing and
disease progression. Moreover, these data suggest a major role of innate immunity through
activation of TLRs on skin APCs in pathogenesis of AD.
P3. Probiotics in the Management of Atopic Dermatitis
Jun Hee Yim, M.D., Duk Han Kim, M.D., Mi-Yeon Kim, M.D., Hyung Ok Kim, M.D., Young
Min Park, M.D
Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul,
Korea
knderma@catholic.ac.kr
Background: Recent studies suggest that oral bacteriotherapy with probiotics might be
useful in the management of atopic dermatitis.
Objectives: The purpose of this investigation was to evaluate the efficacy and safety of
treatment with probiotics in adult atopic dermatitis as well as that of childhood.
Methods: 60 patients with mild to moderate atopic dermatitis were recruited in the treatment
of a mixture of four probiotic strains (Lactobacillus rhamnosus, L. plantarum, L. casei,
Bifidobacterium lactis) twice daily for 8 weeks. The degree of pruritus was determined by
using the 10-point visual analogue scale and the patients’ subjective evaluations (ie, better,
unchanged, or worse) were assessed every other week.
The clinical severity of the eczema was evaluated by using eczema area and severity index
(EASI). As laboratory markers, total IgE, eosinophil cationic protein in serum and cytokine
production (IL-2, IL-4, IL-10, IFN-gamma, TGF-beta) by peripheral blood mononuclear cells
were measured.
Results: Of the 60 mild to moderate atopic dermatitis patients enrolled in the study, 3
patients dropped out due to diarrhea, abdominal pain or aggravation of atopic dermatitis and
7 patients were lost to follow-up. After treatment, 81% of the patients experienced
improvement of the eczema and 65% of the patients experienced improvement of pruritus.
Conclusions: A mixture of four probiotic strains was beneficial in the management of atopic
dermatitis. Thus, probiotic approach may offer a benefical direction in maintaining atopic
dermatitis in a stable state as a supplemental therapy.
P4. The IgE-Bearing B-Cell Receptor Repertoire of Atopic Dermatitis Patients Shows
Unbiased VH-Usage but Patient-Speciﬁc Clonal Expansions Regardless of Serum IgE
Levels
Martin Mempe, Anke Gauger, Christina Schnopp, Johannes Ring, Markus Ollert, Philippe
Kourilsky and Annick Lim
Department of Dermatology and Allergy, TU Munich and Department of Immunology,
Pasteur Institute, Paris
m.mempel@lrz.tum.de
Previous studies have postulated a bias in the usage of IgE-associated VH-chains in atopic
individuals favouring a preferential usage of the VH6 segment. We have analyzed CD19-sorted
B-lymphocytes from several adult atopic eczema patients displaying very high serum IgE levels
(41000 IU/ml). These purified B-cells were screened in a quantitative Real-Time RT-PCR
technique for their transcription of all eight VH-genes together with CH-primers of the e-, g1-4,
and m-type, representative for the repertoire of IgE-, IgG-, and IgM-families. The VH-CHe
amplifications were analyzed for their complementary determining region 3 (CDR3) spectra by a
modified Immunoscope technique. In some patients, clonal expansions were further sequenced
and compared to corresponding expansions of the IgM and IgG transcripts in order to screen
for somatic mutations of the expanded clones and/or commonly selected clones. Serum IgE
levels and antigen-specific IgE were determined using the IMMULITE system.
Our approach revealed a preferential usage of VH3b-, VH4-, and VH1-chains in IgE-
producing B-cells regardless of the individual sensitization pattern. These chains were also
preferentially found in IgG and IgM transcripts. Each patient, however, harbored specific clonal
expansions which were identified by the CDR3-spectratyping and which were not shared
between patients even in cases of highly similar specific IgE production. Extensive sequence
analysis revealed unique CDR3-sequences showing somatic mutations. However, sporadic
clonal sequences were shared between IgE- and IgG transcripts suggesting a common origin.
Atopic individuals with high IgE levels show a highly individual pattern of IgE-bearing B-cell
expansions with no preferential VH-usage but particular CDR3-composition.
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Session 3: Infection and Imunity
KL5. The Role of Infection in Atopic Dermatitis
Donald Y. M. Leung, M.D., Ph.D
Denver, Colorado
Infection plays an important role in atopic dermatitis (AD). Much research has focused on
Staphylococcus aureus, which appears to mediate its proinflammatory effects at least in part
via the production of superantigens. Epicutaneous application of superantigens induces
eczema and enhances Th2 skin responses. Most AD patients make specific IgE antibodies
directed against staphylococcal superantigens; and these IgE anti-superantigens correlate
with skin disease severity. Superantigens also induce corticosteroid resistance, expand skin
homing Tcells and subvert T regulatory cell activity suggesting that several mechanisms exist
by which superantigens increase AD severity.
Increased binding of S. aureus to skin is driven by underlying AD skin inflammation. This is
clinically supported by studies demonstrating that treatment with topical corticosteroids or
calcineurin inhibitors reduces S. aureus counts on atopic skin.In experimental animal models,
S. aureus binding was significantly greater at skin sites with Th2-, as compared to Th1-,
mediated skin inflammation due to IL-4 induced expression of fibronectin. AD skin has also
been found to be deficient in antimicrobial peptides needed for host defense against bacteria,
fungi and viruses. Thus, once S. aureus binds to AD skin, inadequate local host defense
allows bacteria to colonize and grow. The lack of skin innate immune responses predisposes
these patients to infection.
Patients with AD also have an increased propensity toward disseminated viral skin
infections with herpes simplex or vaccinia virus (VV). Investigations into eczema vaccinatum
have intensified due to recent interest in mass smallpox vaccinations since 10–20% of
children have AD and these children carry a life-long susceptibility to eczema vaccinatum.
Interestingly, we have found that skin explants from AD patients support significantly higher
levels of VV replication as compared to normal or psoriasis skin. Conversely, VV stimulation
induces higher levels of LL-37 gene and protein expression in psoriasis skin and normal skin
as compared to AD skin. Stimulation of human keratinocytes with VV induces LL-37
expression. However, IL-4/IL-13 down-regulates the expression of LL-37 in VV-stimulated
keratinocytes. Additionally, VV replication significantly increases in keratinocytes treated with
IL-4/IL-13. Using antibodies to IL-4/IL-13, we have demonstrated that neutralization of Th2
cytokines in AD skin augments LL-37 expression and inhibits VV replication.
Since LL-37 kill VV, its reduction in AD may predispose AD patients to eczema vaccinatum.
The mechanisms for these reduced antimicrobial properties in AD skin appear to be due to a
combination of increased IL-4, IL-10 and IL-13. New strategies for controlling propensity for
viral infection in AD may include downregulation of Th2 cytokine expression in AD or
development of drugs with cathelicidin-like activities which can be used as anti-viral agents.
IC2. Inﬂammatory Reactions to S. Aureus in AD
Thomas Werfel
Dept. Dermatology and Allergology, Hannover Medical University, Germany
It has been well established that atopic dermatitis (AD) disease is complicated by the
concurrent skin colonization with Staphylococcus aureus. Many, but not all, S. aureus strains
carry the capacity to produce exotoxins with superantigenic properties able to activate Tcells
in an unspecific manner. In this context local application of superantigens triggers recruitment
and activation of T cells in and to the dermis. More recently, staphylococcal superantigens
have been shown to inhibit the suppressive function of regulatory T cells of AD patients.
Furthermore, a number of patients suffering from severe AD respond to staphyloccocal
exotoxines with a specific immune response which is associated with detectable specific T-
cell responses and specific IgE levels in the circulation. Since AD improves also in patients
colonized with non-toxigenic S. aureus strains upon antimicrobial treatment, other S. aureus
derived factors must be involved in the pathogenesis of AD. As shown by us recently, a high
percentage of these bacteria is able to produce a-toxin, a pore forming cytotoxin. A wide
range of human cells, among them keratinocytes and lymphocytes, tend to lysis by a-toxin
with greatly varying susceptibility. In keratinocytes, TNF-a is released subsequently to lysis.
Sublytic concentrations of a-toxin have paradox stimulating effects on human T cells which
respond very efficiently with proliferation and IFN-gamma secretion to a-toxin. Since
enhanced staphylococcal colonization is obviously not due to defects in acquired immunity,
recent research on impaired responses to Staph aureus in AD was focussed on the innate
immune system: Some studies have reported that epidermal keratinocytes in AD are
incapable to up-regulate the production of some antimicrobial peptides (HBD-2, HBD-3,
LL24) and that the combination of IL-4 and IL-13 inhibits the gene expression of those
peptides. These findings point to the fact that the lack of these peptides may indeed account
for the susceptibility of AD patients to bacterial infections in the skin compartment. In
addition, a single nucleotide polymorphism (SNP) for TLR-2 (TLR-2 R753Q in the intracellular
portion of the receptor) has been described which is associated with S. aureus infections.
Interestingly, heterozygous AD-patients with the mutant TLR-2 R753Q allele exhibited a
unique phenotype characterized by severe eczema (median SCORAD score 56 pts ranging
from 30 to 90.5 pts) and high IgE levels in cohort investigated recently by us. None of them
had a SCORAD scoreo30 pts, whereas the median SCORAD score of the non-polymorphic
AD group was 45 pts (15 to 89 pts; min–max values). Since cell wall constituents of
staphylococcal aureus are known to directly interact with TLR2, this polymorphism may also
be involved in the susceptibility of AD patients to staphylococcal infections of the skin.
OC9. Th2 Cytokines Down-Regulate Cathelicidin Expression and Increase Skin
Susceptibility to Viral Infection in Atopic Dermatitis (AD) Patients
Michael D Howell, Mark Boguniewicz, Joanne E Streib, Cathy Wong, Richard L Gallo,
Donald YM Leung
National Jewish Medical and Research Center
howellm@njc.org
Patients with atopic dermatitis (AD) are susceptible to the development of eczema herpeticum
and eczema vaccinatum. The development of these potentially life-threatening and disfiguring
viral infections in AD patients is not well understood. Therefore despite renewed interest in mass
vacation against smallpox, the CDC currently recommends that AD patients should not be
voluntarily vaccinated against smallpox even after they have outgrown AD. Previously our group
demonstrated that the cathelicidin anti-microbial peptide family exhibits anti-viral activity
against vaccinia virus (VV) and is deficient in AD skin. Current studies were carried out to better
understand the relationship between VV replication and cathelicidin expression in AD versus
normal skin. Viral replication and cathelicidin expression were evaluated in cultured
keratinocytes as well as skin explants from non-lesional AD (n¼6), psoriasis (n¼6) or normal
skin (n¼ 7) using real-time RT-PCR and immunohistochemistry. VV-DNA directed RNA
polymerase gene expression was measured as an indicator of viral replication. Stimulation of
keratinocytes with VV induced cathelicidin expression in a time- and dose-dependent manner
(po0.05). Addition of VV to skin explants resulted in significantly (po0.05) higher levels of viral
replication in AD (4854  2240ng VV-DNA directed RNA polymerase) as compared to normal
(519  26) and psoriasis (807  242). Conversely, VV induced higher levels of cathelicidin gene
(po0.05) and protein (po0.05) expression in skin from psoriasis patients and normal subjects
as compared to AD patients. Treatment with IL-4 and IL-13 prior to infection down-regulated
(po0.001) the expression of cathelicidin in VV-stimulated keratinocytes. Additionally, viral
replication significantly increased (po0.001) from 12760  1263ng to 21280  4814 in
keratinocytes treated with IL-4 and IL-13. Using antibodies to IL-4 and IL-13, we found that
neutralization of Th2 cytokines in AD skin augmented LL-37 expression and inhibited viral
replication. Th2 cytokines in AD skin may block cathelicidin expression. Since cathelicidins kill
VV, its reduction may potentiate VV replication in AD skin and predispose AD patients to adverse
reactions from smallpox vaccination. Investigations are in progress to determine whether a
deficiency in LL-37 accounts for increased susceptibility of AD patients to eczema herpeticum.
OC10. Microanalysis of Anti-Microbial Peptide, beta-Defensin-2, in the Stratum Corneum
from Atopic Dermatitis Patients
Seiko Asano, Makoto Kawashima, Yoshiaki Ichikawa, Genji Imokawa
Tokyo Women’s Medical University and Kao Biological Science Laboratories, Japan
seiko-a@wb3.so-net.ne.jp
We have previously reported the possibility that vulnerability to bacterial colonization in the
skin of patients with AD is associated with reduced levels of a natural anti-microbial agent,
sphingosine, which results from decreased levels of ceramides as a substrate and from
diminished activities of its metabolic enzyme, acid ceramidase. On the other hand,
antimicrobial peptides such as defensin and cathelicidin have recently been elucidated to
play an important role in host defense and cutaneous innate immunity. Although beta-
defensin-2 is reported to be down-regulated in the whole skin of AD compared with psoriasis,
little is known about their role in the colonization of S. aureus in the stratum corneum from AD
patients, because a precise evaluation of these peptides for the quantitation in the stratum
corneum as a front anti-microbial barrier against S. aureus colonization has not been yet
performed. In this study, we have developed microanalysis of beta-defensin-2 in the stratum
corneum by combination of immunoprecipitation and Western blotting and compared beta-
defensin-2 content (expressed as ng/micro-g keratin) between AD and healthy control.
Microanalysis revealed that beta-defensin-2 in the stratum corneum significantly increases in
the AD lesion and occurs at a similar level in the AD non-lesion compared with healthy
control. The beta-defensin-2 in the lesional skin also increases in proportion to the severity of
AD. The counting of bacterial colonies revealed that there is a higher population of S. aureus
on the lesional and non-lesional skin surface of patients with AD compared with healthy
controls. Comparison between the colony counting and beta-defensin-2 in the same skin
sites demonstrated that there is a positive correlation (r¼ 0.460, p¼ 0.021, n¼ 25) between
these factors. Collectively, these findings suggest that beta-defensin-2 becomes inducible in
response to bacteria, injury or inflammatory stimuli and is not associated with vulnerability to
S. aureus colonization in the skin of patients with AD.
ABSTRACTS 597125 : 3 SEPTEMBER 2005
OC11. The Balance Between Langerhans Cells and Inﬂammatory Dendritic Epidermal
Cells as a Regulator of Immunogenic and Tolerogenic Immune Responses in Atopic
Eczema
Natalija Novak, MD1, Jean-Pierre Allam, MD1, Brigitte Schlu¨tter-Bo¨hmer1, Thomas Bieber1,
Bartlomiej Kwiek1,2
(1) Department of Dermatology, University of Bonn, Germany, (2) Department of
Dermatology, University of Warsaw, Poland
Natalija.Novak@ukb.uni-bonn.de
Two different dendritic cell subtypes are the key players in the epidermal skin lesions of atopic
eczema (AE): Langerhans cells (LC), which are localized in the lesional and non-lesional skin
and Inflammatory Dendritic Epidermal Cells (IDEC), which are recruited into the skin at the
initiation of AE and only present at inflammatory epidermal sites. Considering the
pathophysiology of AE, IDEC are regarded as the main amplifiers of immunogenic allergic
inflammatory immune responses in the skin, while LC have been shown to be capable to
some degree to induce immuno-tolerance in a constantly antigen exposed epidermal
environment. Data supporting the idea of a critical balance between LC and IDEC in AE in this
context are still lacking. In the last decade, calcineurin inhibitors such as tacrolimus (FK506)
have been successfully introduced as an effective treatment of AE. Furthermore it has been
described that tacrolimus treatment diminishes the number of IDEC cells in the skin and
restores the physiological supremacy of LC, although the underlying immune mechanism
leading to this phenomenon remains unknown.
We observed that treatment of differentiating DC from patients with AE with tacrolimus
induces the production of transforming-growth factor (TGF)-beta2 and TGF-beta3 by DC,
which triggers the generation of high numbers of LC in a TGF-beta-dependent manner.
Further on tacrolimus modifies the expression co-stimulatory and co-inhibitory molecules
involved in the induction of tolerogenic mechanisms such as B7-H1, B7-H2, B7-H3 molecules
on the surface of LC while decreasing the stimulatory capacity of LC toward autologeous and
allogeneic T-cells in T-cell proliferation assays.
Interestingly, the down-regulation of the stimulatory capacity of tacrolimus-treated LC
corresponds with the induction of T-cells with a high IL-10 and TGF-beta producing capacity.
Beside that we could show that the suppression of T-cell responses initiated by tacrolimus-
treated LC is dependent on the presence of CD4þCD25þ regulatory T-cell subsets within
the T-cell fraction. These mechanisms are dependent on LC/T-cell -contact and revertible by
the addition of IL-2 to the T-cell culture, which is known to inhibit suppressive functions of
CD4þCD25þT-cells. From our data a picture emerges that the tacrolimus-promoted
differentiation of LC from precursor cells recruited into the skin and DC present within the skin
might skew the balance from immunogenic IDEC toward tolerogenic LC and lead to an
overbalance of tolerogenic LC which are capable to induce functionally active regulatory T-
cells. Moreover, the introduced principle of a critical interplay between IDEC and LC in AE,
designating the outcome of either a tolerogenic or an immunogenic state in the skin opens a
new way for therapeutic strategies. These might be aimed to target and facilitate the function
of LC as potential natural silencers of allergic-inflammatory immune responses.
P5. Aberrant Blood Dendritic Cells in Atopic Dermatitis
Cristina Lebre, Toni van Capel, Martien Kapsenberg, Jan Bos and Esther de Jong
Academic Medical Center, Amsterdam, The Netherlands
e.c.dejong@amc.uva.nl
Dendritic cells (DC) are professional antigen presenting cells that play a pivotal role in the
orchestration of Th cell responses. Myeloid (BDCA1) and plasmacytoid (BDCA4 and
interferon-producing cells) DC have been described, that differ in their responsiveness to
pathogenic compounds and their cytokine production profile. The function of these DC
subsets in atopic disorders is not well studied. Therefore, we compared the frequency and
cytokine profile of these subsets in peripheral blood from AD patients and healthy controls.
No differences were found in the frequencies or the expression of the T cell stimulatory
molecule HLA-DR and the T cell co-stimulatory molecules CD86 and CD83. Analyzing their
cytokine producing capacity, we found no differences in the production of pro-inflammatory
TNF-alpha or anti-inflammatory IL-10 in BDCA1 or BDCA4 cells. However, BDCA1 and
BDCA4 DC from AD patients showed a selectively and strongly reduced capacity to produce
the Th1-polarizing cytokine IL-12p70, and the anti-viral and Th1-polarizing cytokine IFN-
alpha, respectively. Since reduced IL-12 or type I IFNs may promote Th2-biased responses,
these data suggest that DC from AD patients have a role in the induction or maintenance of
the Th2-associated allergic response. Moreover, reduced anti-viral IFN-alpha production by
BDCA4 cells may be instrumental in the increased susceptibility to virus infection in AD.
Session 4: Epidermal Inﬂammation Including Neurogenic Inﬂammation and Pruritus
KL6. Chemokines in Atopic Dermatitis
Bernhard Homey
Dept. of Dermatology, Heinrich-Heine-University Du¨sseldorf, Germany
Atopic dermatitis is a chronic or chronically relapsing inflammatory skin disease with
eczematous lesions demonstrating typical morphology and distribution, severe pruritus,
elevated serum IgE, the presence of allergen-specific IgE, and peripheral blood eosinophilia.
The prevalence of atopic dermatitis rapidly increased during the past decades and is
currently ranging between 10–20% in children and 1–3% in adults. Histopathologically, the
lesional skin of atopic dermatitis patients shows a dermal infiltrate consisting of mainly
activated cutaneous lymphocyte associated antigen (CLA)þ memory T cells (CD44CD8) and
antigen-presenting cells (APC). Among the APC population, lesional skin shows increased
numbers of Langerhans cells (LC), inflammatory dendritic epidermal cells (IDEC), as well as
dermal dendritic cells which show markedly upregulated expression of Fc receptors for IgE
on their cell surface. Moreover, dermal sites of atopic skin demonstrate extensive deposition
of eosinophil-derived proteins or more rarely intact eosinophils. Exposure to allergens, e.g.
house dust mite antigens, or microbial products plays an important role in the initiation and
maintenance of atopic skin inflammation. In early phases of the disease, memory T cells with
a TH2 phenotype infiltrate the atopic skin; however, chronic lichenified atopic dermatitis
lesions are characterized by the dominance of skin-infiltrating TH1 cells.
In the past decade, numerous studies identified chemokines associated with atopic
dermatitis. These chemokines include CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL13,
CCL17, CCL18, CCL20, CCL22, CCL26, CCL27, and CX3CL1. Notably, serum levels of
CCL11, CCL17, CCL18, CCL22, CCL26, CCL27 and CX3CL1 directly correlated with disease
severity suggesting an important role in the immunopathogenesis of atopic dermatitis.
Among these chemokines, CCL1, CCL17, CCL18, CCL22 and CCL27 are likely candidates to
critically regulate the recruitment of memory T cells to sites of atopic skin inflammation. Here
an overview is provided of the role of chemokines in the complex immunopathogenesis of
atopic dermatitis, highlighting potential areas for therapeutic intervention.
IC3. Is Atopic Dermatitis a Neurogenic Inﬂammatory Disease?
Uwe Gieler
Psychosomatic Medicine Justus-Liebig-University Giessen Ludwigstrae 76 D 35392
Giessen, Germany
Uwe.Gieler@psycho.med.uni-giessen.de
Newer studies try to point out the close connection between epidermal nerve fibers and brain,
together with new developments in brain research and studies with neuropeptides in skin
diseases which are mainly involved with epidermal nerve fibers (Undem et al 2000). In the
past years it becomes more and more evident that atopy-relevant effector cells, such as mast
cells and Langerhans cells form a close anatomical relationship with nerve fibers staining
positive for a number of neuroactive substances, for instance substance P, vasoacitve
peptide or Neutrophine Growth Factor NGF (Gieler et al 2002). Regarding this close
anatomical relationship of nerve terminals and effector cells in atopic eczema, it seems
possible that stress-induced stimulation of nerve fibers induces secretion of neuroactive
substances. There are a growing number of studies indicating that atopic eczema patients
show disturbances in neuroimmunological pathways so that some authors stated that
psychological stress may be conceptualized as a social pollutant that, when ‘breathed’ into
the body, may disrupt biological systems related to inflammation through mechanisms
potentially overlapping with those altered by physical pollutants and toxicants’ (Wright et al
2005). Functional changes in the hypothalamus-pituitary-adrenal cortex-axis are under
discussion. Buske-Kirschbaum compiled an overview of the psychobiological aspects of
atopic eczema and confirmed by means of hypotheses the various endocrine, immunological
and psychophysiological influences on atopic eczema (Buske-Kirschbaum et al. (2001).
Recent studies demonstrated also stress-induced alterations in permeability barrier home-
ostasis, mediated by increased endogenous glucocorticoids (Choi et al 2005) so the
existence of a neurogenous inflammation reaction in atopic dermatitis seems to be present.
The influence of serious events in life and of stressors of various degrees on the immune
system is known (Kodama et al 1999). The autonomic nervous system acts as the connector
between feelings and subsequent somatic response. Lymph nodes contain sympathic
afferents; adrenergic and cholinergic fibers are found in the thymus, the lymphocytes also
have adrenergic and cholinergic receptors.
Kupfer (1994) examined the interaction between the severity of skin symptoms, the
expression of individual emotions and the excretion of salivary cortisol and salivary IgA.
Aggression, depression and anxiety were found to be emotions particularly related to skin
symptoms. The central immunoetological role of neuropeptides such as NGF and BDNF as
well as histamine, acetylcholoin and ECF-A (Eosinophil-Chemotactic Factor of anaphylaxis) in
atopic eczema patients were delineated.
Buske-Kirschbaum A, Geiben A, Hellhammer D: (2001) Psychobiological Aspects of Atopic
Dermatitis: An Overview. Psychotherapy and Psychosomatics 70: 6–16
Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, Feingold KR (2005)
Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis
and stratum corneum integrity. J Invest Dermatol. 2005;124:587–95
Gieler U, Niemeier V, Brosig B (2002) Psychoimmunology and Evaluation of Therapeutic
Approaches. in: Atopic Dermatitis (T Bieber, DYM Leung eds.). Marcel Dekker Inc. New York, Basel
Kodama A, Horikawa T, Suzuki T, Ajiki W, Takashima T, Harada S, Ichihasha M (1999) Effects of
stress on atopic dermatitis: investigations in patients after the great Hanshin earthquake. J Allergy
Clin Immunol 104:173–176
Kupfer J, Gieler U, Braun A, Niemeier V, Huzler C, Renz H (2001) Stress and Atopic Eczema. Int
Arch Allergy Immunol 124: 353–355
Steinman L (2005) Elaborate interactions between the immune and nervous systems. Nat
Immunol. 2004;5:575–581
Undem BJ, Kajekar R, Hunter DD, Myers AC. Neural integration and allergic disease; J Allergy
Clin Immunol 2000.106:213–220
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IC4. Anxiety and Atopic Dermatitis
Masahiro Takigawa, Shigeho Shirahama, Taiko Sakamoto, Hideo Hashizume
Department of Dermatology, Hamamatsu University Sch Med, Hamamatsu 431-3192, Japan
takigawa@hama-med.ac.jp
It has been well documented that emotional and psychological stresses bring on attacks or
cause exacerbation of skin symptoms in atopic dermatitis (AD). Recent studies have revealed
that stress elaborates anxiety on one hand and affects immune functions on the other. State-
Trait Anxiety Inventory (STAI) is a self-administered questionnaire of 20 questions concerning
trait anxiety (TA; the anxiety felt in general) and 20 concerning state anxiety (SA; the anxiety
felt at present). STAI is scored from a minimum of 20 (the lowest level of anxiety) to a
maximum of 80 (the highest level of anxiety) on each scale. With the use of STAI, we have
shown that, while having higher anxiety levels than normal individuals, AD patients with
stronger perception of TA than SA enhanced serum IgE synthesis. Serum total IgE levels were
highly correlated with ratios of TA/SA, indicating that those with higher TA levels compared
with SA levels had elevated serum IgE. In accordance with this finding, Th1/Th2 ratios as
assessed by interferon-producing cell numbers/IL-4-producing cell numbers were correlated
inversely with TA and the ratio of TA/SA. Anxiety did not correlate with the severity of
dermatitis, itching or eosinophil number. We suggest that persistent stress stimulates a Th2
immune response in AD through preferential elaboration of TA. Stressors stimulate the
hypothalamus-pituitary-adrenal axis and sympathetic nervous system, releasing adrenal
glucocorticosteroids and norepinephrin, respectively, and thus tilt cuntaneous inflammation
toward the Th2 response.
The patients with AD are suffering from intolerable itching night and day, which is triggered by
physiological and psychic stimuli. The patients are not always benefited through antagonizing
histamine. We carried out an open trial to examine the effect of tandospirone, a serotonin 1A
receptor agonist exerting anti-anxiety effects, 30mg per day for 4 weeks, on relief of skin
symptoms in adult AD patients. In the patients with TA/SA of41.0, the TA/SA ratio significantly
decreased when treated with tandospirone compared to without it. Moreover, itching as
measured by VAS decreased more significantly in the treated group than the non-treated group
among the patients with intense anxiety (TA/SA41.0 and TA445). Our findings suggest
attenuation of itching by successful control of mental stresses with tranquilizers.
In conclusion, everyday stressors may repeatedly stimulate a Th2 immune response to prevent
attenuation of skin inflammation from regulatory immune mechanism, resulting in protraction of
inflammatory responses. Intervention with sedatives can be a part of the management strategy in
stress-associated itching in AD patients and possibly beyond.
OC12. Intracellular Control of CTACK/CCL27 (Cutaneous T Cell Attracting Chemokine)
in Keratinocytes through the Nuclear Transcription Factor Kappa B (NF-kB)
Christian Vestergaard, Claus Johansen, Kristian Otkjaer, Lars Iversen and Mette Deleuran
Department of Dermatology, Aarhus University Hospital, Denmark
chr-vest@post9.tele.dk
The CC-chemokine CTACK/CCL27 is highly expressed in inflammatory skin disorders such
as atopic dermatitis, psoriasis and contact dermatitis. CTACK binds to the chemokine
receptor CCR10 which is highly expressed on skin homing CLAþ (cutaneous lymphocyte
associated antigen) lymphocytes. CTACK is along with the CC-chemokine TARC/CCL17
(thymus and activation-regulated chemokine) considered as pivotal chemokines in the
attraction of lymphocytes to the inflamed skin in atopic dermatitis.
NF-kB is a dimeric protein made up as a hetero- or homodimer from the proteins belonging
to the Rel family of proteins (RelA (p65), RelB, cRel, p52 and p50), and plays a vital role in
inflammation through control of transcription of genes for chemokines and proinflammatory
cytokines.
CTACK production is induced in keratinocytes by TNF-alpha, and it is well known that TNF-
alpha is a potent activator of NF-kB. Thus, our hypothesis was that inhibition of NF-kB would
also inhibit the TNF-alpha induced CTACK production.
We inhibited TNF-alpha induced CTACK production in keratinocytes using the non-specific
NF-kB inhibitors sodium salicylate, 3,4-dichloroisocoumarin, and phenylarsine oxide. To
substantiate the results and to further investigate which components of NF-kB are involved in
the TNF-alpha induced CTACK production in keratinocytes we incubated the keratinocytes
with antisense oligonucleotides against p50 and p65 (three targets each) and found that these
potently inhibited CTACK production both alone and together. This indicates that the NF-kB
molecule controlling CTACK production is a heterodimer consisting of p50 and p65.
Recent results have shown that deletion of certain IkB molecules, which under normal
circumstances retain the NF-kB molecule in the cytoplasm of the skin and inhibit their
function, lead to conditions that resemble atopic dermatitis. Although it is still speculative, we
suggest that defects in the NF-kB system play a central role in the process leading to
inflammation in the skin in atopic dermatitis.
OC13. Brain-Derived Neurotrophic Factor Exerts Immunomodulatory Functions in Atopic
Dermatitis
Ulrike Raap, Alexander Kapp, Bettina Wedi
Department of Dermatology and Allergology, Hannover Medical University, Germany
mail@ulrike-raap.de
Recent studies have gained widespread attention to the complex regulation of genetic,
environmental, immunologic and pharmacologic factors that contribute to the development
of atopic dermatitis (AD). However, neuroimmune interactions of this chronic inflammatory
skin disease still remain to be elucidated. The aim of this study was to assess the functional
role of the neurotrophin brain-derived neurotrophic factor (BDNF) on highly purified peripheral
blood eosinophils of AD and non-atopic subjects.
BDNF receptor expression (p75NTR and trkB) was higher on AD eosinophils compared with
that seen in nonatopic subjects (po0.05–0.001). Eosinophil apoptosis was inhibited by BDNF
(po0.01–0.01) and chemotactic index was increased (po0.001) in BDNF stimulated AD
eosinophils, whereas this effect was not shown in nonatopic subjects. In addition, BDNF
levels were increased intracellularly and in supernatants of AD eosinophils compared with
nonatopic subjects (po0.05–0.001). Taken together, this study provides the first evidence for
a functional role of BDNF on AD eosinophils probably mediated by an increased expression of
BDNF receptors. In addition, higher intracellular BDNF levels and the release of BDNF by
eosinophils underline the particular importance of BDNF in patients with AD, pointing to new
pathophysiologic aspects of this chronic inflammatory skin disase.
OC14. Increased Expression and a Potential Anti-Inﬂammatory Role of TRAIL in Atopic
Dermatitis
E. Vassina, M. Leverkus#, L. R. Braatheny, H-U. Simon and D. Simony
Department of Pharmacology, University of Bern, Bern, Switzerland, #Department of
Dermatology, University of Magdeburg, Magdeburg, Germany, and the yDepartment of
Dermatology, University of Bern, Bern, Switzerland
dagmar.simon@insel.ch
Background: TRAIL, the tumor necrosis factor-related apoptosis-inducing ligand, induces
apoptosis of many transformed but also of non-transformed cells. In addition, TRAIL receptor
activation has been reported to activate non-apoptotic signaling pathways. This study was
aimed to investigate the expression and a potential role of TRAIL in atopic dermatitis (AD).
Patients and Methods: Skin biopsies and/or blood samples were taken from 10 patients with
AD and 9 healthy controls. TRAIL expression was detected by flow cytometry and by
immunofluorescence staining followed by confocal microscopy. In vitro TRAIL-induced
interleukin (IL)-1 receptor antagonist expression by HaCat cells was measured by RNase
protection assay and ELISA. IL-1 receptor antagonist expression in AD skin was stained by an
immunofluorescence technique.
Results: We observed an increased expression of TRAIL in peripheral blood T cells and
monocytes from patients with AD compared to control individuals. High TRAIL expression
was also observed in skin-infiltrating T cells of atopic dermatitis patients. Topical tacrolimus
treatment reduced the total number of T cells in the skin, but the relative proportion of TRAIL
positive cells within both CD4þand CD8þ cell populations did not change. TRAIL was
demonstrated to induce the expression of interleukin-1 receptor antagonist in keratinocytes
in a caspase-independent manner in vitro. Moreover, increased expression of interleukin-1
receptor antagonist was observed in keratinocytes of AD lesional skin.
Conclusion: These data suggest that TRAIL expressing inflammatory skin cells may
contribute to the epidermal activation of the interleukin-1 receptor antagonist gene in AD.
OC15. Graphology and Atopic Dermatitis
Gelmetti C, Fabrizi G#, Colonna C, Guerriero C#, Vizziello P, Tarantino V#, Centofanti C#,
Galdo G#
Unit of Pediatric Dermatology, Universita` Statale di Milano, #Milano and Universita`
Cattolica del Sacro Cuore, Rome, Italy
carlo.gelmetti@unimi.it
Rook and Wilkinson consider the management of emotional factors to be of significance in 40
percent of patients attending departments of dermatology(1). The main types of host factors
that can influence stress (genetics, perception) and the numerous types of stressors
(environmental, behavioral, psychological) have been studied by dermatologists together with
the possible role of neuropeptides in the pathogenesis of some common dermatoses (2).
Despite this recognition, systematic study of the interaction and application of principles
derived from areas of psychosomatic research are lacking. Clinical experience seems to
indicate that for some patients, psychosocial stress is a factor in the precipitation or
exacerbation of their illness and in some cases indeed the major factor. Psoriasis, vitiligo,
atopic dermatitis (AD) and alopecia areata more than other dermatoses illustrate the subtle
interactions between genetic predisposition, environmental influences and psychosocial
factors that must take place before the disease become manifest. In particular, recent studies
suggest that AD patients with a higher anxiety level are more likely to improve their
psychologic and dermatologic condition after psychotherapy, but are more vulnerable to
nonadherence when no adequate psychologic treatment is offered (3). Graphology can be a
useful tool in spotting health problems before they become too severe, and is excellent at
identifying stress in the individual (4). The aim of our study was to detect psychosomatic
components in AD through the systematic study of handwriting. The possibility of detecting
specific deficiencies, such as physical weakness, poor memory, anxiety, stress, depression
and lack of confidence can be identified by graphology. Preliminary results indicate that the
quality of handwriting not only can be disturbed in AD patients but the same can be modified
in the course of the disease. Despite the fact that some authors question its predictive validity
(5), graphology could help therapists identify hidden problems and plan a more specific and
tailor-made treatment.
1. Rook AJ, Wilkinson DS: in Rook AJ, Wilkinson DS, Ebling FJG (eds): Textbook of
Dermatology. (3rd ed), London, Blackwell, 1979, pp 2023–2035.
2. Panconesi E, Hautmann G. Psychophysiology of stress in dermatology. The psychobiologic
pattern of psychosomatics. Dermatol Clin. 1996;14:399–421.
3. Linnet J, Jemec GB. Anxiety level and severity of skin condition predicts outcome of
psychotherapy in atopic dermatitis patients. Int J Dermatol. 2001;40:632–6.
4. Brewer JF. Graphology. Complement Ther Nurs Midwifery. 1999;5:6–14.
5. King RN, Koehler DJ. Illusory correlations in graphological inference. J Exp Psychol Appl.
2000;6:336–48.
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KL7. A Novel View on the Natural History of Atopic Dermatitis
Thomas Bieber, MD, PhD
Department of Dermatology, University of Bonn, Germany
Progress in molecular genetics, epidemiology and immunology have provided new tools to
study in more depth the pathophysiology of atopic dermatitis (AD). In this context and by
using a more stringent definition of atopy and atopic diseases, scientists realized that
eczematous diseases looking like AD may be distinguished in at least 2 entities: AD stricto
sensu and ‘‘eczema’’ (without the context of atopic sensitization, i.e. former intrinsic form of
AD) (Johannsson et al, JACI 2004). Most intringingly, positional cloning approach has shown
more similarities between gene loci for AD and psoriasis than between AD and asthma. This
finding is rather surprising and challenges the concept of atopic march. Moreover, candidate
gene approach has unravelled differences between AD and eczema in the incidence of single
nucleotide polymorphisms (SNPs) in genes such as IL-4Ra or IL13.
Epidemiological studies revealed that in infants AD-like skin lesions often start in the
absence of specific IgE, strongly implying that IgE sensitization is not a prerequisite for
eczematous lesions and may occur secondarily to cutaneous inflammation. Whether this
inflammatory reaction may be driven solely by e.g. food allergen specific T cells which have
been shown to be detectable very early in life remains to be clarified. Moreover, in animal
models it has been shown that an OVA specific IgE response, asthma and inflammatory skin
lesions can be mounted by repeated topical application. On the other hand, specific IgE
towards self-proteins such as structural proteins from keratinocytes have been shown to be
common in adults AD patients with highly elevated serum IgE suggesting the possibility of an
autoimmune scenario occurring in the context of AD and evolving from mechanisms of
molecular mimicry based on initial IgE response to highly conserved microbial structures as it
seems to be the case for MnSOD.
Thus, based on these observations a new picture of the natural history of AD emerges
where the disease may start as ‘‘eczema’’ and – depending of the gene sets involved – may
evolve in a typical AD stricto sensu. This is then followed by autosensitization with specific
IgE response to self proteins. However, the pathophysiological significance of these IgE
remains to be proven. If this turns to be the case, autosensitization may explain why
prevention measures such as allergen avoidance are less efficient in patients with a longer
history of AD. This – admittedly speculative – view of the natural history of AD should be
verified in the context of birth cohorts and ultimately enforce the concept of early intervention
and the development of disease modifying strategies.
IC5. Autoreactivity in Atopic Dermatitis—Induced by Skin Fungi? IgE- and T Cell
Mediated Autoimmunity Against Manganese Superoxide Dismutase in Atopic Dermatitis
Peter Schmid-Grendelmeier,,z, Sabine Flu¨ckigerz, Rainer Disch
R
, Axel Trautmann,
Brunello Wu¨thrichz, Kurt Blaser, Annika Scheyniusy and Reto Crameri
zAllergy Unit, Dept. of Dermatology, University of Zu¨rich, CH-8091 Zu¨rich, Switzerland,
Swiss Institute for Allergy and Asthma Research (SIAF) CH-7270 Davos, Switzerland;
zBioVisioN Schweiz AG, CH-7270 Davos, Switzerland;
R
Alexanderhausklinik, CH-7270
Davos, Switzerland and yDept. of Medicine, Unit of Clinical Allergy Research, Karolinska
Institute and Hospital, Stockholm, Sweden
peter.schmid@usz.ch
Autoreactivity to human proteins has been postulated as a decisive pathogenetic factor for
patients with atopic dermatitis (AD) on the basis of the detection of IgE directed against
various proteins in vitro. In this study, an essential, stress-inducible enzyme—human
manganese superoxide dismutase (hMnSOD), known for its autoreactivity in ABPA—was
found to act also as an autoallergen in a subset of patients with AD, clearly demonstrated by
eczematous reactions through atopy patch tests with the application of recombinant
hMnSOD. Human MnSOD also induced positive skin prick test results in 29 of 69 patients
with AD in addition to IgE- and T cell–mediated in vitro reactivity. Interestingly, such reactivity
was also found in patients with nonatopic eczema and strongly correlated with disease
severity. All patients reacting to hMnSOD were sensitized against the skin-colonizing yeast
Malassezia sympodialis, known for its pathogenetic role in AD. MnSOD of fungal origin and
MnSOD of human origin show a strong structural relationship. Thus, sensitization is most
likely induced by exposure to environmental fungal MnSOD of M sympodialis, resulting in
molecular mimicry due to secondary autoreactivity with its human counterpart. Further
studies will have to elucidate now whether consequent anti-inflammatory or antifungal
treatment might prevent such potentially harmful phenomena in AD.
OC16. Expression of Thymic Stromal Lymphopoietin (TSLP) in Keratinocytes of Atopic
Dermatitis Patients and Normal Controls
Chang Ook Park M.D., Wu Wen Hao M.D., Ju Hee Lee M.D., Ph.D., and Kwang Hoon Lee
M.D., Ph.D.
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei, Korea
kwanglee@yumc.yonsei.ac.kr
Human thymic stromal lymphopoietin (TSLP) is a novel IL-7-like cytokine produced by human
epithelial, stromal, and mast cells. TSLP-activated human DCs produce Th2-attracting
chemokines such as TARC and MDC but not IL-12. TSLP-DCs induce the generation of
CD4þTh cells with a pro-allergic phenotype and also induce the differentiation of CD8þT
cells into IL-5 and IL-13-producing cytolytic effector cells. It has been reported that TSLP is
highly expressed in the lesional keratinocytes of atopic dermatitis but not in the non-lesional
keratinocytes of atopic dermatitis and other types of disease with skin inflammation. We
performed our study to verify the differential expression of TSLP in keratinocytes among
lesional, non-lesional sites of atopic dermatitis and normal control. We also observed the
expression of TSLP in keratinocytes treated with various cytokines. Our study shows that
TSLP is expressed all by keratinocytes of normal controls, lesional and non-lesional sites of
atopic dermatitis patients. However, TSLP is much highly expressed in lesional keratinocytes
of atopic dermatitis than in non-lesional and normal keratinocytes using confocal laser
microscopy and immunohistochemistry methods. TSLP expressions did not differ among
keratinocytes treated with IL-4, TNF-alpha, TGF-beta and KGF.
OC17. Identiﬁcation of Malassezia Sympodialis in Patients with Atopic Dermatitis by
Polymerase Chain Reaction and its Impact on Disease Activity
Antonie Roll, Nada Juricevic, Peter Schmid-Grendelmeier
Allergy Unit, Department of Dermatology, University Hospital of Zurich, Switzerland
antonie.roll@usz.ch
Background: In recent years Malassezia sympodialis has received particular attention in the
pathogenesis of atopic dermatitis (AD). The existing evidence suggests that both IgE- and T-
cell mediated immune reactions could be involved. However, investigations to demonstrate
the significance of colonization with this yeast and sensitization to it are scarce since
Malassezia spp. are more difficult to isolate and culture than other pathogenic yeasts.
Objective: This study was aimed at the identification of Malassezia sympodialis in patients
with AD by establishing a DNA-based procedure directly applicable to pathological skin
scales, at the sensitization rate against Malassezia sympodialis among AD patients and the
yeast’s influence on disease activity.
Methods: Sera from 52 patients suffering from AD and 10 healthy controls were investigated
for specific IgE against Malassezia sympodialis and the scoring index (SCORAD) of all AD
patients assessed. In addition, Malassezia sympodialis DNA was extracted from skin scales
of three different localizations by a modified hexadecyltrimethylammonium bromide (CTAB)
method and amplified by single polymerase chain reaction (PCR), using the general fungal
ITS 1/4 primers for amplification of sequences from the Malassezia major ribosomal DNA
complex.
Results: Malassezia-specific IgE were positive in 24/52 patients (46.2%) and in none of the
healthy controls. DNA could be extracted from skin scales of 36 patients (69.2%), mainly from
affected skin scales, less from the neck and unaffected skin. Only 2/10 (20%) of the healthy
controls showed colonization with the yeast. There was no significant correlation between
SCORAD and colonization with Malassezia sympodialis, SCORAD and sensitization rate or
sensitization rate and colonization (p40.05).
Conclusions: These results eviscerate the role of Malassezia sympodialis in AD since there is
no clear explanation for the occurrence of specific IgE without colonization or increased
SCORAD and vice versa. However, this finding may also imply a support from adjuvant
factors in the sera or skin of AD patients. The importance and relative contribution of
Malassezia sympodialis sensitization to AD remains to be established.
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OC18. High Concentrations of Circulating Macrophage Migration Inhibitory Factor in
Patients with ‘Extrinsic’ Atopic Dermatitis
Jung-Soo Kim, MS, Dong-Soo Yu, MD, Jin-Wou Kim, MD
Departments of Dermatology, Uijeongbu St. Mary’s Hospital, The Catholic University of
Korea, Korea
JWKIM52@catholic.ac.kr
Background: The most employed diagnostic criteria of atopic dermatitis (AD) can be fulfilled
in the absence of elevated total circulating IgE or specific IgE to food allergens or
environmental aeroallergens and in the absence of personal or familial history of atopy as
well. Therefore a distinction between ‘extrinsic’ or ‘allergic’ and ‘intrinsic’ or ‘non-allergic’ AD
has been suggested. Macrophage migration inhibitory factor (MIF) is a pleiotrophic
lymphocyte and macrophage cytokine; it is likely to play an important role in innate immunity.
Serum MIF content was significantly elevated in patients with AD and PBMCs should be an
important source of increased serum MIF in AD.
Objective: This study was designed to investigate the differences of plasma MIF levels
between ‘extrinsic’ and ‘intrinsic’ AD and the correlation between plasma MIF levels, total
plasma IgE levels and house dust mite (HDM) allergen-specific IgEs.
Methods: Plasma MIF levels were measured by an enzyme-linked immunosorbent assay in
116 healthy controls and 265 AD. The plasma levels of the total and HDM allergen-specific
IgEs were measured by a latex photometry immunoassay and enzyme-linked immunoabsor-
bent assay in patients with AD. Differences between groups were nonparametrically
statistical analysis by using Kruskall-Wallis test.
Results: Plasma MIF and log [total IgE] levels were significantly increased in AD patients
compared with control subjects (P¼ 0.0028 and Po0.0001, respectively). Plasma MIF
concentrations in atopic dermatitis patients were significantly positively correlated with the
specific IgE D.farinae score (r¼0.17, Po0.01). The differences of MIF levels between the two
AD subgroups and control group were statistically significant (P¼ 0.0005).
Conclusion: Increased MIF levels are associated with AD symptoms and MIF may become a
useful clinical parameter to understand the ‘extrinsic’ AD.
OC19. Elevated Serum Levels of I-309/CCL1 in Patients with Severe Atopic Dermatitis
Naoyuki Higashi, MD, PhD, Yayoi Niimi, MD, PhD, Youko Kato, MD, Seiji Kawana, MD, PhD
Department of Dermatology, Nippon Medical School, Tokyo, Japan
ton@nms.ac.jp
Background: Th2 lymphocytes, which play a critical role in the pathogenesis of atopic
dermatitis (AD), employ the CC chemokine receptors CCR4 and CCR8 with the legands
thymus- and activation-regulated chemokine (TARC/CCL17), macrophage-derived chemo-
kine (MDC/CCL22) and I-309/CCL1. It has already been reported that TARC/CCL17 and
MDC/CCL22 were elevated in sera from patients with AD. There has been one recent report
of I-309/CCL1 in the pathogenesis of AD patients (J Immunol. 2005 174:5082-91).
Objective: The aim of this study was to clarify the participation of I-309/CCL1 in the
pathogenesis of AD.
Methods: Forty-seven patients aged 18 to 64 years with mild to severe AD and 9 healthy
volunteers aged 26 to 45 years were examined. Disease severity was determined by Rajka &
Langeland grading. Thirty-eight patients were subdivided into three groups by disease
severity: mild (score 3–4; n¼ 16), moderate (score 4.5–7.5; n¼ 17) and severe (score 8–9;
n¼ 5). The serum I-309/CCL1 level was measured through the use of ELISA. The limit of
detection was 0.7 pg/ml. The relationships between I-309/CCL1 levels and various laboratory
values, such as lactate dehydrogenase (LDH), IgE, eosinophil numbers in peripheral blood,
and eosinophil cationic protein (ECP) were analyzed. Immunohistochemical staining of a skin
section with anti-I-309/CCL1 Ab was performed using the avidin-biotin-alkaline phosphatase
system as a preliminary study.
Results: The serum I-309/CCL1 levels of patients with AD and of control subjects were
4.21þ /4.88 pg/ml and 0.62þ /0.67 pg/ml (Meanþ /SD), respectively. There was a
statistically significant difference between the AD and control subjects (p¼ 0.0007). We
compared the serum I-309/CCL1 levels among the 3 groups of patients with AD. The I-309/
CCL1 levels in patients with severe AD were significantly higher than in patients with mild AD
(p¼ 0.0288), but were not higher than those with moderate AD. The serum I-309/CCL1 levels
correlated with eosinophil numbers in peripheral blood (r¼0.529) and LDH (r¼ 0.617),
whereas the serum IgE levels weakly correlated with I-309/CCL1 levels (r¼0.47). We
evaluated the serum I-309/CCL1 levels in 10 patients with AD during the clinical course.
Disease severity decreased in all patients after the treatment (p¼ 0.0051). However, serum I-
309/CCL1 levels did not decrease after the treatment. Specifically, serum I-309/CCL1 levels
increased after the treatment in 2 patients who had high serum I-309/CCL1 levels before the
treatment. The preliminary results of immunohistochemical analysis showed that dermal
endothelial cells markedly expressed I-309/CCL1 protein in lesional atopic skin in
comparison with normal skin.
Conclusion: Elevated levels of I-309/CCL1 were clearly shown in the serum of patients with
AD in comparison with the levels in control subjects, and it was demonstrated that the levels
of I-309/CCL1 correlated with the serum LDH levels, which are reported to represent the
disease severity of AD. Although there was actually a very small amount of I-309/CCL1
compared with TARC/CCL17 in the serum of AD patients, we precisely detected I-309/CCL1
in the serum from AD patients and demonstrated a correlation between the level of I-309/
CCL1 and the LDH level or the eosinophil numbers in peripheral blood. We concluded that
serum I-309/CCL1 levels could be one of the markers of disease severity for AD.
OC20. Serum Levels of IL-16 and Disease Activity in Children with Atopic Dermatitis
Barbara Pigozzi, Elena Tonin and Anna Belloni Fortina
Dermatology Unit, Department of Pediatrics, University of Padua, Italy
belloni@pediatria.unipd.it
Background: Il-16 is a natural ligand of CD4 molecules and induces chemotaxis in CD4-
expressing cells. It amplifies the inflammatory reaction by stimulating cytokine production in
monocytes and activating T-cells. Evidence has been accumulated that IL-16 plays a role in
the pathogenesis of atopic dermatitis and increased serum levels of IL-16 have been
detected in autoimmune and allergic diseases. However few data are available on IL-16
serum levels in atopic dermatitis. (1,2)
Aim: to evaluate IL-16 serum levels in childhood atopic dermatitis before and after treatment
in order to obtain data of a possible correlation between IL-16 serum levels and other clinical
markers of disease severity and activity.
Methods: We measured by an ELISA approach, IL-16 serum levels in 34 children (18 males
and 16 females; mean age 6,5 years), with moderate to severe atopic dermatitis at their first
visit and after 3 months of treatment and in 10 non atopic sex and age-matched healthy
controls. In the children with atopic dermatitis we also evaluated other clinical markers of
disease activity (e.g. SCORAD index, serum IgE values, peripheral eosinophil counts).
Results: IL-16 serum levels were significantly higher in patients affected by atopic dermatitis
than in controls at the beginning of the observation, as well as after 3 months of treatment
with tacrolimus. However no clear correlation was found between IL-16 serum levels and the
other clinical markers.
Conclusion: Our preliminary results, while showing increased levels of serum IL-16 in
children with atopic dermatitis, seem to raise some doubts on the use of IL-16 serum level as
a marker of disease activity in childhood atopic dermatitis.
1. Frezzolini A, Paradisi M., Zaffiro A., Provini A., Cadoni S., Ruffelli M., De Pita` O. Circulating
interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel
serological marker of disease activity. Allergy 2002;57:815–20
2. Masuda K, Katoh N, Okuda F, Kishimoto S. Increased levels of serum interleukin-16 in adult
type atopic dermatitis. Acta Derm Venereol 2003;83:249–53.
OC21. Effect of Caring for a Child With Atopic Dermatitis and Asthma on Parental Sleep,
Depression and Anxiety Scores: A Prospective Comparative Study
Kate Moore, Timothy J David, Clare S Murray, Helen F Child, Peter D Arkwright
University of Manchester, United Kingdom
peter_arkwright@lineone.net
Objective: To compare the relative impact of caring for a child with atopic dermatitis and
asthma on parents’ sleep and level of anxiety/depression.
Design: Prospective, descriptive, questionnaire-based study.
Setting: Regional specialist eczema and asthma outpatient clinics at a tertiary paediatric
hospital in the UK.
Participants: 91 parents (55 mothers and 37 fathers) with children who had moderate to
severe atopic dermatitis or asthma, but not both.
Main outcome measures: Number of sleep disturbances and minutes the mother and father
were up with their child during the previous two nights. Mothers’ and fathers’ hospital anxiety
and depression scale scores.
Results: Mothers caring for children with moderate to severe atopic dermatitis lost a median
of 39 minutes of sleep/night and fathers lost 45 minutes sleep/night. This compared with a
median of no sleep lost by parents who had children with asthma (Po0.001). Multi-variant
analysis showed that these results were independent of the age of the children. Within these
families, there was a direct correlation between the severity of sleep disturbance and the level
of maternal depression (rho¼0.73; Po0.001) and anxiety (rho¼ 0.58; P¼0.002), as well as
with the level of paternal anxiety (rho¼0.59; P¼ 0.01).
Conclusions: Compared with looking after a child with chronic asthma, caring for a child with
chronic atopic dermatitis was associated with significantly higher parental sleep distur-
bances. Sleep disturbances correlated strongly with the parental anxiety levels, and in the
case of mothers, depression scores.
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OC22. Flare Cycles, Itch-scratch Loops and Associated Downturns in QoL: The Human
and Economic Burden of Atopic Dermatitis on Patients and Caregivers
Florian Turk, PhD, MSc Econ
Novartis Pharma AG Basel, Switzerland
florian.turk@novartis.com
Objective: Atopic dermatitis (AD) is a chronic, cyclical, relapsing, inflammatory skin
condition. Flare cycles, development of visible skin lesions and aggravation of the ‘itch-
scratch-cycle’ during acute flare-ups of AD form the basis for significant impact on quality of
life for children and their caregivers as well as for adult patients. The aim of this study is to
gather information on the human and economic impact of AD and to examine which factors
are the most important determinants of QoL of patients and caregivers.
Method: ISOLATE is the first large-scale, international survey to assess the impact of AD on
the patients, care-givers and society. A total of 2,002 patients (413 yrs) and caregivers of
children (2–13yrs) with moderate to severe AD from 8 countries were surveyed. Beside other
instruments PIQoL-AD, QoLIAD, EQ-5D and an assessment of work productivity loss are
included in the study. Multiple regression are used to evaluate which factors significantly
impact QoL scores and the cost of illness are calculated. Cross-sectional QoL scores are
evaluated between demographic groups and according to disease-related factors; age
groups are created based on distributions to enable statistical analyses; continuous variables
were grouped to facilitate statistical tests; correlations were calculated (Spearman Rank) and
non-parametric tests for independent samples (Mann-Whitney U Test for two groups or
Kruskal-Wallis One-way Analysis of Variance for three or more groups) are employed.
Results: The QoL of AD-sufferers is mainly affected by unhappiness and depression due to
flare-up. The most important other factors for QoLIAD are percentage of performance at work
affected, percentage of body affected, severity of itch, severity of eczema and the number of
nights woken during flare-up. 33.6% of the variance is accounted for by this model, of which
20.8% is represented by how unhappy/depressed the flare-up made. Downturns in QoL of
caregivers are primarily due to the nights woken during flare-up. Additional important
explanatory variables are percentage of body affected, percentage of performance at school
affected, unhappiness/depression due to child’s flare-up, bright redness of AD, concerns
over eczema treatments and days taken off school. 27.8% of the variance is accounted for by
this model, with 10% of this variance represented by the number of nights that the child is
woken due to having a flare-up.
Patients report mean utility values of .783, caregivers of .79. Statistical significant between group
differences exists for severity of the disease, days of work (patients and caregivers), hospitalization,
percent of work affected (caregivers) and number of nights sleep affected (patients).
Costs of AD are mainly driven by social costs due to absenteeism and presenteeism and direct
medical costs. The impact of AD on labour market costs and social welfare loss is significant.
P6. Comparative Efﬁcacy of Haniﬁn and Rajka’s Criteria and U.K. Working Party’s
Diagnostic Criteria in Diagnosis of Atopic Dermatitis in a Hospital Setting
A.J. Kanwar
Department of Dermatology, Postgraduate Institute of Medical Education and Research,
Chandigarh 160012, India
ajkanwar@sify.com
Background: Diagnosis of atopic dermatitis depends on clinical features as no definitive
diagnostic test exists. Hanifin and Rajka’s criteria were acceptable for hospital based studies
but were found not to be suitable for field studies. U.K. working party formulated a clinical
diagnostic criteria that could be used both in hospital and epidemiological setting. Validation
studies of the criteria showed widely variable results, probably due to different clinical
settings and ethnicity.
Aim and objective: This study was undertaken to validate Hanifin and Rajka’s criteria and to
assesss the comparative efficacy of Hanifin and Rajka’s criteria and U.K. working party’s
diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India.
Subjects and methods: This study serially included 101 patients of atopic dermatitis and 48
controls of paediatric age group. The study period was from July 2003 to December 2004.
Results: Hanifin and Rajka’s criteria (senstivity- 96%, specificity- 93.75%, positive predictive
value- 97% and negative predictive value- 91.84%) had statistical advantage over U.K.
working party’s diagnostic criteria (sensitivity- 86%, specificity- 95.83%, PPV- 97.75% and
NPV- 76.67%) with p-valueo0.005.
P7. Atopic Dermatitis & the Adolescent Patient
Alain Taı¨eb
Hoˆpital St Andre´, Bordeaux on behalf of the ISOLATE study group, France
alain.taieb@chu-bordeaux.fr
Background: Visible skin lesions and intense itching significantly impact the quality of life of
patients with AD. Adolescents are a particularly vulnerable group of AD patients as they are at
a critical life stage where personal appearance, interaction with peers and educational
performance begin to matter. ISOLATE is the first international, large-scale survey to provide
insight into how adolescent patients view the impact AD flares have on their lives and their
attitude towards current treatment options.
Methods: 2,002 patients (413 yrs) or their caregivers (children 2–13 yrs) with moderate to
severe AD, from 8 countries underwent in-depth telephone interviews utilising a compre-
hensive questionnaire developed in collaboration with national eczema patient groups and
physicians. A flare was defined as inflammation of the skin requiring a physician consultation
or application of prescription medication. The results for the (n¼ 125) adolescent patients
(14-17 yrs) are reported here.
Results: Adolescent AD patients experience on average 8 flares and spend more than 3.5
months in relapse each year. The flare causes extreme itching in 60% of adolescent patients
and prevents 83% of them from participating in everyday activities. ISOLATE demonstrates
how the stigma of AD can affect the adolescent patient’s mood, self-confidence and ability to
conduct relationships. While in flare 70% of adolescents are embarrassed about their
appearance; 52% feel unhappy or depressed; 36% agree that their self-confidence is
affected; 23% worry that it will make it more difficult to form relationships with a boyfriend or
girlfriend and 53% are either always or sometimes worried about their next relapse.
Despite the emotional impact of AD on adolescent patients, 66% have not discussed their
feelings with their physician. 46% of adolescent patients report that the flare has an effect on
their school life and 39% have been teased or bullied due to their AD. 41% of adolescent
patients agree that during a flare their concentration is affected while at school, which may
partly be explained by disturbed sleep experienced for an average of 12 out of 15 nights per
flare. The majority of adolescent patients are prescribed reactive use of topical
corticosteroids (TCS) to control the AD flare, however, 51% are concerned about the use
of these agents due to side effects and 65% use TCS only as a last resort. 68% of adolescent
patients stated that being able to effectively control their AD would be the single most
important improvement to their quality of life.
Conclusions: ISOLATE demonstrates the significant impact AD has on adolescent patients
quality of life; the strong desire they have to gain control over their condition; their concern
about the use of TCS treatment regimens and the urgent need to improve long-term
management strategies for this vulnerable group. This survey was supported by an
educational grant from Novartis.
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KL8. Canine Atopic Dermatitis: A Natural Model to Study the Human Disease
T Olivry
NC State University College of Veterinary Medicine, Raleigh, North Carolina, USA
For decades, a pruritic skin disease diagnosed as atopic dermatitis (AD) has been identified in
dogs living in a natural environment. This disease usually occurs first in juveniles or young
adults, and there is a clear breed and family predisposition. Limited data suggest that the
prevalence of canine AD may be increasing. Canine AD may occur in association with allergic
rhinitis and conjunctivitis, but signs of asthma are uncommon. The most common allergenic
flare factors for canine AD are of environmental – especially Dermatophagoides farinae house
dust mite – and dietary origin. Clinical signs of canine AD include erythema and secondary
skin lesions that occur predominantly on the face, paws, axillae, groin, perineum and flexural
aspects of the limbs. Dogs with AD exhibit common cutaneous infections with either
Staphylococci or Malassezia organisms. There is good evidence suggesting that topical or
oral glucocorticoids and the calcineurin inhibitors cyclosporine and tacrolimus are the most
effective to alleviate signs of AD in dogs. Immunologically, canine AD is usually associated
with high serum levels of allergen-specific IgE, but such reaginic antibodies are absent from
rare individuals. Additionally, skin lesions of canine AD resemble those of its human
counterpart at both cellular and mediator levels. In both spontaneously or experimentally
sensitized dogs, the epicutaneous application of allergens to which the subjects are
hypersensitive triggers an inflammatory reaction that mirrors lesions of natural AD. In
summary, the epidemiology, clinical signs, treatment outcome and immunological aberrations
of canine AD make this spontaneous dog model relevant to study the pathogenesis of AD or
test novel interventions to prevent or treat this disease in humans.
IC 6. Spontaneous Dermatitis in Mice Transgenic for Human Apolipoprotein C1
Perry Verzaal1, Arnold P. Oranje2, Leslie van der Fits2,3, Pauline Ja¨ger1, Patrick Rensen4,
Louis Havekes1,4, Errol Prens2,3 and Lex Nagelkerken1
1.Divison Biomedical Research, TNO Quality of Life, Leiden, The Netherlands; 2. Depart-
ment of Dermatology, Erasmus MC, Rotterdam, The Netherlands; 3. Department of
Immunology, Erasmus MC, Rotterdam, The Netherlands; 4. Departments of Cardiology
and Internal Medicine, Leiden University Medical center, Leiden, The Netherlands
Mice with transgenic overexpression of human apolipoprotein C1 (APOC1) in liver and skin
have strongly increased serum levels of cholesterol, triglycerides and free fatty acids,
indicative for a disturbed lipid metabolism.
Importantly, these mice spontaneously develop symptoms of dermatitis from an age of 7
weeks on including pruritus, erythema and lichenfication. Pruritus was quantified by an
accelerometer and this revealed significantly increased scratching in APOC1 mice as
compared to wild-type mice; the scratching intensity increased during aging of these mice.
Also these mice show a loss of skin-barrier function evident from increased Trans Epidermal
Water Loss (TEWL). Histological analysis show increased epidermal thickening together with
elevated numbers of inflammatory cells in dermis and epidermis.
Daily topical treatment with triamcinolone acetonide (0.1% in cream) for a period of 3
weeks, starting at an age of 9 weeks, significantly reduced several aspects of dermatitis, as
demonstrated by reduction of the pruritus and decreased epidermal thickening. These data
indicate that the APOC1 transgenic mouse represents a spontaneous model of dermatitis
that is sensitive to treatment with corticosteroids. Our current research focuses on the
validation of the APOC1 transgenic mouse as a model of (allergic) atopic dermatitis.
OC23. Establishment of a Mouse Model for Atopic Dermatitis: Getting New Insights into
the Role of T Cells
A. Hennino1, J. Benetie`re1, K. Rodet1, F. Berard2, M. Vocanson1, A-M. Schmitt3, M.-F. Aries3
and J.F. Nicolas1,2
1 INSERM U503, 69675, IFR128, Biosciences Lyon-Gerland, 69365 Lyon; 2 Department of
Clinical Immunology and Allergy, CH Lyon-Sud, 69375 Pierre-Be´nite, France; 3CERPER,
Pierre Fabre Medicament, Toulouse, France
hennino@cervi-lyon.inserm.fr
Mite antigens play important roles in the onset and/or development of atopic dermatitis, and
mite antigen-induced dermatitis model appear beneficial for the basic study of atopic
dermatitis. Therefore to understand the onset and development of the disease appropriate
animal models are essential. Recent studies on eczematous skin diseases such as atopic
dermatitis have shown the role of T cells as effectors of the manifestation of the eczema. In
the current study, we attempted to establish an allergic dermatitis model in normal C57Bl6
mice using as antigen Dermatophagoides farinae (DF) as antigen in order to study the T-cell-
mediated immune effector mechanisms. Mite antigen solution was applied epicutaneously
onto the ear 3 times per week and then the mice were let to rest for another week (cycle of
two weeks). Several cycles were done. After 4 cycles we observed thickening of the
epidermis of the ear and infiltration of the skin by eosinophils and T cells as demonstrated by
immunohistological and RT-PCR analysis. Levels of total IgE were mildly increased (factor 2).
Furthermore, DF-specific splenocytes and draining lymph nodes cells (as well as CD8þT
cells) were isolated from lymph nodes and spleens of sensitised mice. In an alternative model,
sensitization of naı¨ve mice was obtained by s.c. injection of bone marrow dendritic cells
(BMDC) charged with DF. Seven days later, mice were challenged by a topical application of
DP onto the ear and the ear swelling was measured. This model offers the advantage of a
quicker sensitization (7 days instead of 41 days) and the possibility of depleting selectively
discrete T cell populations and study the impact to the development of the DF-induced
dermatitis.
OC24. Collared Mice: A Model to Assess the Effects of Scratching
Satoshi Takeuchi, Fumiko Takeuchi, Furue Masutaka and Stephen I. Katz
Dermatology Branch, National Cancer Institute, NIH, Bethesda, MD, USA and Department
of Dermatology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
takeuchs@dermatol.med.kyushu-u.ac.jp
There is no current in vitro or in vivo method to easily assess itching despite its clinical
importance in various skin diseases, such as atopic dermatitis, in which itching is a primary or
secondary symptom. The purpose of this study was to determine the effect of scratching on
the development of contact hypersensitivity (CH), an experimental model of allergic skin
reactions, and to assess itching as a physiological response using a murine model of CH. We
utilized plastic collars which were placed around the neck to prevent the mice from
scratching (or grooming) their ears during CH. Following elicitation, the ear swelling of
collared mice was significantly decreased, by 41–51%, compared to control mice in which
collars were not used. Thus, we conclude that scratching contributes considerably to the
increase in ear thickness that is seen in CH in mice. This model thus enables us to assess
itching as a part of the CH skin reaction, and may be suitable to assess or screen anti-pruritic
agents or new drugs. We therefore assessed the effect of various agents like antihistamines
(chlorpheniramine), steroids (prednisolone), non-steroidal anti-inflammatory agents (aspirin)
and sedative agents (phenobarbital) on CH, and found that all of these agents decreased CH
(by approximately 36–54%, depending on the time between elicitation and drug adminis-
tration) when collars were not used. Notably, sedative agents had anti-pruritic properties
without any anti-inflammatory effects, since they had no apparent effect on CH in collared
mice, while the other anti-pruritic or anti-inflammatory agents caused 31–60% decreases of
CH in the collared mice. We also explored for factors involved in the decrease of CH in
collared mice using Affymetrix Genechip technology. Among 39,000 genes, a total of 135
genes were consistently and differentially regulated (124 up- and 11 down-regulated) during
CH in collared mice as compared to controls; 2 immune-response genes were downregulated
and 7 immune-modulating genes were upregulated in collared mice. This model thus enables
us to better dissect out the various elements responsible for the elicitation of CH without the
confounding scratching that occurs during these reactions.
OC25. Rapid and Speciﬁc Acoustic Analysis of Itch in AD Model Mouse
Hitoshi Mizutani, Kouji Umeda, Kazuya Tokime, Youichi Omoto
Department of Dermatology, Mie University, Japan
h-mizuta@clin.medic.mie-u.ac.jp
Scratching is an essential and skin specific behavior resultant from itch – a common
symptom for acute and chronic dermatitis, especially atopic dermatitis (AD). Close
association between itch sensation and scratching, measurement of the scratching times
has been used for evaluation of the itching in animals. Manual counting of the visual images of
the experimental animals has difficulty in accuracy and reproduction. Recent introduced
digital image analysis for mouse scratching needs handling of huge sized records with
manual correction for blind angles. To measure scratch behavior of the atopic dermatitis
models, we have developed a novel acoustic measuring system. AD model mice (IL-18Tg)
develop scratching sounds, which were digitally recorded and analyzed using novel
computer software we have developed. The mice scratched over 20 times/sec., which was
untraceable by manual counting. This system counted within a few minutes the scratching
times of the model mice recorded for a hour, and clearly revealed in vivo effects of anti-
allergic drugs. Different from visual recording, this system does not need strong illumination.
Acoustic measurement enables long time recording of the mice scratching under less
stressful conditions, and is a potent tool for the development of new therapies for AD.
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KL9. Netherton Syndrome as a Model for Skin Barrier Dysfunction
Alain Hovnanian
Inserm U563 and Department of Medical Genetics, Purpan Hospital, BP3028, 31024
Toulouse cedex 3, France
alain.hovnanian@toulouse.inserm.fr
Epidermal proteases play a major role in the differentiation and the desquamation processes
of the epidermis. The recent identification of SPINK5 encoding the serine protease inhibitor
LEKTI as the defective gene in Netherton syndrome (NS) provided the first exemple of a
human skin disease caused by defective inhibition of epidermal serine proteases. We
generated Spink5-null mice which faithfully replicate key features of NS, including abnormal
desquamation, impaired keratinization, hair malformation and a skin barrier defect. LEKTI
deficiency in mice causes Stratum Corneum Tryptic Enzyme (SCTE) and Stratum Corneum
Chymotryptic Enzyme-like (SCCE) hyperactivity, resulting in desmoglein 1 degradation and
abnormal desmosome cleavage in the upper granular layer. This leads to defective stratum
corneum adhesion and resultant loss of skin barrier function, from which the animals die
within a few hours of birth. Profilaggrin processing is increased, loricrin and involucrin are
overexpressed, implicating LEKTI in the cornification process. Intercellular adhesion is lost in
the inner root sheath and hair shafts are irregular and shrunk. Transplantation experiments of
whole skin from Spink5 knock-out mice reproduce major histological changes similar to NS
patients: the epidermis is hyperproliferative, showing acanthosis, papillomatosis and
hypogranulosis, while the stratum corneum is thicker and shows detachment; hair follicles
display a pronounced disorganisation and an inflammatory infiltrate is present in the papillary
dermis. This work identifies LEKTI as a key regulator of epidermal protease activity, with
profound effects on epidermal desquamation, the cornification process and hair formation.
IC7. Stratum Corneum pH Regulates Permeability Barrier Homeostasis
Jean-Pierre Hachem, M.D., Ph.D
Academsiche Ziekenhuis – Vrije Universiteit Brussel Department of Dermatology Laarbeek-
laan 101 1090-Brussels
Jeanpierre.Hachem@az.vub.ac.be
Providing the interface with a desiccating external milieu, the primary function of the stratum
corneum (SC) is to limit excess transcutaneous water loss from the aqueous interior. Whereas the
acidic surface mantle of the skin was first described over a century ago, other than its putative
antimicrobial activity, its functions remain largely unknown. At least three endogenous
mechanisms: a) free fatty acid generation from phospholipid hydrolysis, b) a sodium-proton
antiporter (NHE1), and c) histidine metabolism to urocanic acid, acidify either whole stratum
corneum (SC), inner vs. outer SC, or specific membrane microdomains. NHE1 localizes to the
outer nucleated cell layers and its expression is regulated by changes in surface surface pH
independtly from barrier status. Unlike most epithelia, epidermal NHE1 expression increases by
SC neutralization and is downregulated by lowering SC pH. Acidification, however, regulates the
key SC functions: permeability barrier homeostasis, integrity/cohesion, and antimicrobial activity.
We have recently shown that permeability barrier recovery is delayed by even short application of
superbases, compounds that are 10 times more basic than in 1N sodium hydroxide. The pH-
dependent mechanism that was found to be responsible for the barrier abnormality involves the
requirement of an acidic pH for the maximal catalytic activity of certain lipid processing enzymes;
e. g., b-glucocerebrosidase (bGlcCer’ase) and acidic shyngomyelinase (aSMase). In contrast to
transient pH alterations, sustained SC neutralization altered not only barrier recovery kinetics, but
also basal barrier function. These barrier abnormalities were attributable to decreased
aˆGlcCer’ase and aSMase catalytic activity due to serine protease (SP)-mediated enzyme
degradation, normalized by co-applied SP inhibitors (SPI). In addition, either: a) short-term
exposure of intact skin to neutral pH buffers b) elevation of SC pH by blockade of an endogenous
acidifying mechanism or c) short- and long-term applications of superbases compromise SC
integrity/cohesion, attributable to accelerated corneodesmosome (CD) degradation. These
deleterious effects were also further linked to SP activation, because co-applied SPI normalized
both SC integrity/cohesion and CD degradation, even in the face of an elevated pH. Sustained
elevations in SC pH are an appropriate model for neonatal skin, which displays normal basal
barrier function, but abnormalities in both barrier recovery and SC integrity/cohesion. In addition,
many skin diseases, including psoriasis, atopic dermatitis, and other eczemas are associated
with prolonged increases in SC pH. One could speculate that such a sustained increase in SC pH
could either trigger, exacerbate, or prolong the manifestations of these disorders. In these clinical
situations, the pH-induced decrease in either SC integrity/cohesion and/or permeability barrier
homeostasis, could further aggravate disease-specific disturbances in SC function.
IC8. Kallikreins in the Stratum Corneum
Maria Brattsand, Kristina Stefansson and Torbjo¨rn Egelrud
Department of Public Health and Clinical Medicine, Dermatology and Venereology, Umea
University, Umea, Sweden
maria.brattsand@dermven.umu.se
In our group, our main interest for the last 20 years has been to understand the process of
desquamation. To keep the skin barrier intact, it is very important to have a well regulated
proteolysis at the skin surface that is in balance with the de novo production of keratinocytes
at the basal cell layer in stratum corneum. This balance is often disturbed in different skin
disorders like atopic dermatitis and psoriasis for example. We have now biochemically
purified three different serine proteases in active form from the outermost parts of stratum
corneum. All three enzymes, stratum corneum tryptic enzyme (SCTE or kallikrein 5), stratum
corneum chymotryptic enzyme (SCCE or kallikrein 7) and kallikrein 14, belong to the same
gene family, the tissue kallikreins. Both kallikrein 5 and 7 are thought to be involved in the
desquamation process. They show a similar expression pattern in the outermost parts of the
stratum corneum, and they have been shown to be able to degrade desmosomes at
physiological pH. The function of kallikrein 14 is not known, but it is a protein with high tryptic
activity. The expression pattern of kallikrein 14 is different compared to the other two
proteins. Immunohistochemistry shows predominant staining of the sweat glands. All three
proteins can be detected on the outermost surface by analysis of the protein content of tape
strips.
All three enzymes are produced as inactive prepro-enzymes that are exported to the
outside of the cells. To become active, a proteolytic cleavage by an enzyme with tryptic
cleavage specificity of the pro-peptide is required. We have shown that kallikrein 5 can
activate itself as well as kallikrein 7 and 14 in a pH dependant manner that may have
physiologic implications. Most of kallikrein 14 that is found in the stratum corneum is in its
activated form, while quite a large proportion of both kallikrein 5 and 7 can be found as
inactive pre-forms.
OC26. Epicutaneous Sensitization to Aeroallergens in Infantile Atopic Dermatitis:
Determining the Role of Epidermal Barrier Impairment
Franck Boralevi1, Thomas Hubiche1, Christine Le´aute´-Labre`ze1, Elodie Saubusse2, Sylvie
Maurice-Tison2, Alain Taı¨eb1
1Pediatric Dermatology Unit & Inserm E217 and 2Inserm U593, Bordeaux University
Hospitals, Bordeaux, France
franck.boralevi@chu-bordeaux.fr
Introduction: As already shown by our group, epicutaneous sensitization to atopens
overlaps the onset of atopic dermatitis (AD) in infancy (1). Early epidermal barrier impairment
may facilitate the epicutaneous penetration of atopens. The aim of our study was to
investigate possible correlations between TEWL measures and aeroallergen sensitization
tests in infants with AD.
Patients and methods: This cross-sectional study was carried out in our out-patient unit from
May 2002 to June 2004, in 3 to 12 month-old children with a diagnosis of moderate to severe
AD (UK working party criteria, SCORAD415). After written consent, the following tests were
performed: TEWL (g/m2/h) on non-involved skin (TM210 MonadermR), specific IgE, atopy-
patch test (APT) and skin-prick tests for 7 aeroallergens, i.e., Dermatophagoides
pteronyssinus, D. farinae, cat, dog, birch-pollen, ambrosia, and cockroach. Only APTs with
skin readings of þ þ or more were considered positive. A control group of 29 infants without
AD was enrolled to validate TEWL measures. Environment was assessed by a questionnaire,
and house dust mite (HDM) concentration was measured on dust samples (Acarex-testR).
Results: 89% of AD infants had positive APT to common aeroallergens. With a mean of 27.4
g/m2/h, AD infants had a significant higher TEWL than controls (11.1, po0001). Children with
at least two positive APT had higher TEWL (29 g/m2/h) than those with only one positive APT
(20.75, po0.035). Moreover, TEWL increased with AD severity, with a mean TEWL of 34.4 in
children with SCORAD440 and 23.7 in children with SCORADo40 (po0.05). No correlation
was found between indoor APT results and exposure to HDM, cat and dog at home.
Discussion: Our study confirms a high prevalence of delayed sensitization to in- and out-
door aeroallergens in AD infants. It also confirms in infants a positive correlation between AD
severity (SCORAD) and epidermal barrier impairment (TEWL) previously noted by Seidenari
et al. in older children [2]. Since we showed that the higher the TEWL, the higher the
prevalence of sensitization to aeroallergens, our data argue for an early and provocative role
of a constitutive epidermal barrier impairment for atopen sensitization in infantile AD.
1. Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact
Dermatitis. 1999;41:177–80.
2. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic
dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved
skin. Acta Derm Venereol 1995; 75: 429–433.
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OC27. Re-Characterization of the Non-Lesional Skin in Association with Barrier Function
and the Severity of Atopic Dermatitis
Hayato Matsuki1, Kimihiro Kiyokane1, Takahiro Matsuki2, Sayuri Sato2 and Genji Imokawa3
(1) Department of Dermatology, Osaka Medical University, Osaka, (2) Sanno Hospital, Tokyo
and (3) Kao Research Laboratories, Tochigi, Japan
imokawag@dream.ocn.ne.jp
The relationship between the severity of atopic dermatitis (AD) and defects in the barrier
function of non-lesional skin of patients with AD is still unclear. To determine whether
disrupted barrier function in the non-lesonal skin is associated with the severity of AD and/or
with local dry skin properties such as dryness/scaling/itchiness, we evaluated the barrier
function and the water content of non-lesional forearm skin and compared that with the
severity of AD and the intensity of dryness/scaling/itchiness at the same skin sites. The
transepidermal water loss (TEWL) significantly increased in proportion to the severity of AD
with a high correlation coefficient (r¼ 0.834, po0.0001, n¼ 106), while the capacitance
decreased in proportion to the severity of AD with a lower correlation coefficient (r¼ 0.720,
po0.0001, n¼106) compared with TEWL. Comparison with dry skin properties revealed that
while the capacitance values were highly correlated with dryness (r¼0.752, po0.0001,
n¼106) and with scaling (r¼0.697, po0.0001, n¼ 106), the TEWL was also related to
dryness (r¼0.788, po0.0001, n¼106) with a higher correlation coefficient compared with
capacitance and to scaling (r¼ 0.697, po0.0001, n¼ 106). Itchiness was more dependent on
capacitance rather than TEWL although they had similar correlation coefficients (r¼0.653
for capacitance and r¼0.660 for TEWL, po0.0001, n¼ 106). While there was a minor
correlation (r¼0.268, po0.028, n¼72) in the non-lesional skin of AD between TEWL and
capacitance, our results suggest that the abnormal barrier functions of non-lesional skin in
AD patients predominantly reflect the severity of AD and are also associated with the intensity
of the dry skin properties in concert with the water condition.
OC28. Re-Evaluation of the Importance of Barrier Dysfunction in the Non-Lesional Dry
Skin of Atopic Dermatitis: Analysis by Topical Application of a Barrier Cream
Takahiro Matsuki1, Sayuri Sato1, Hayato Matsuki2, Kimihiro Kiyokane2, and Genji Imokawa3
(1) Department of Dermatology, Sanno Hospital, Tokyo, (2) Osaka Medical University, Osaka,
and (3) Kao Research Laboratories, Tochigi, Japan
imokawag@dream.ocn.ne
Atopic dermatitis (AD) can be considered a barrier disease in which antigens and irritants that
can easily penetrate clinically normal, non-lesional skin due to its defective barrier function
trigger and worsen the dermatitis. Thus, replenishing the barrier function in clinically normal,
non-lesional skin of patients with AD seems to be a key for preventing the refractory nature of
the dermatitis. To determine whether the disrupted barrier function of AD non-lesional skin
can be repaired by topical application of a synthetic ceramide known to induce barrier
recovery and to subsequently evaluate the relationship between enhanced barrier function
and improved dry skin conditions, we applied topically a synthetic ceramide (CER) or
hirudoid-(HIRU) containing cream to the non-lesional skin of AD patients for 4 weeks and
evaluated their efficacy by measuring trans-epidermal water loss (TEWL) and capacitance
values as well as clinical scoring for scaling/dryness/itchiness. Treatment for 4 weeks with the
CER cream significantly reduced dryness/scaling/itchiness which was accompanied by
significant decreases in TEWL and increases in capacitance values, at 2 and 4 weeks. In
contrast, treatment for 4 weeks with the HIRU cream elicited a similar but lesser reduction in
dryness/scaling/itchiness which was accompanied by significant but lesser decreases and
increases in TEWL and capacitance values, respectively, at 2 and 4 weeks. Comparison of
TEWL and capacitance values during the 4 weeks of treatment with either cream revealed
that whereas the two parameters of CER cream treated skin were generally similar to healthy
control skin, those of the HIRU cream treated skin remained similar to the mild or moderate
AD skin. It is likely that the recovery in barrier function also reflects the improvement in
clinically evaluated dry skin conditions, which suggests that the barrier replenishing effect is a
more important factor for treatment of AD non-lesional skin than is the improvement of water
deficiency.
P8. Skin Barrier Damage: Cause or Consequence of Atopic Dermatitis?
MJ Cork, D Robinson, Y Vasilopoulos, A Ferguson, M Moustafa, R Tazi-Ahnini, SJ Ward
Dermatology-Biomedical Genetics, Division of Genomic Medicine, University of Sheffield,
Medical School, Sheffield, UK
m.j.cork@sheffield.ac.uk
The barrier to the penetration of irritants and allergens into the skin is located in the stratum
corneum; it prevents the loss of water from the host, thereby maintaining internal
homeostasis. The thickness of the stratum corneum varies considerably and is thinnest on
the eyelids and flexural skin sites. Irritants and allergens may interact with sites of
predisposition to atopic dermatitis (AD) that have a low stratum corneum barrier reserve
and are therefore more prone to break down. Corneodesmosomes lock corneocytes together
and prevent them from being dislodged by shearing forces. Corneocytes are shed from the
skin surface by proteolysis, which is mediated by skin-specific proteases, such as stratum
corneum chymotryptic enzyme (SCCE). These proteases are inhibited by skin-specific
protease inhibitors, such as secretory leukocyte protease inhibitor (SLPI). It is essential that
premature desquamation and breakdown of the skin barrier is prevented, a process that can
permit the penetration of irritants and allergens, leading to the development of AD flares.
Recent increased interest in the role of the skin barrier in AD was initially triggered by the
observation that a large proportion of children with AD (30–66%) did not have a raised non-
specific or specific IgE. If these children were not immunologically atopic, how had the clinical
AD developed? We investigated whether part of the genetic basis of AD could be due to
changes in skin-barrier-related genes, such as SCCE. We screened the SCCE gene for
variations and found an AACC insertion in the 3’UTR and then performed a case–control
study, comparing patients with AD with unaffected controls; this demonstrated a strong
genetic association between the AACC insertion and AD. This insertion may result in
increased mRNA stability and increased SCCE protease levels leading to premature
breakdown and thinning of the epidermal barrier. This allows the penetration of irritants
and allergens, and triggers the development of eczematous lesions.
In AD, multiple environmental factors interact with changes in many genes to produce the
disease phenotype. The application of some topical dermatological products can impair the
epidermal barrier, e.g. certain emollients and prolonged use of potent topical corticosteroids.
We used the tape stripping/TEWL method developed by Kao et al (2003)6 to assess epidermal
barrier function after the application of topical corticosteroids (TCs). The very potent TC
clobetasol proprionate caused a major deterioration in skin barrier function after applying
twice-daily for 5 days to normal human volunteer skin. The application of the potent TC
betamethasone valerate 0.1% also damaged the skin barrier, but it took longer (15 days).
There is increasing evidence that one of the primary genetic defects in AD is in skin-barrier-
related genes such as SCCE. This makes the skin barrier vulnerable to the penetration of
irritants and allergens, which trigger AD flares. Environmental factors such as soap,
detergents, exogenous proteases and very potent TCs may interact with the defective
barrier in a genetically predisposed individual to unmask/exacerbate AD. Understanding the
detrimental effects of TCs on the skin barrier, helps us learn how best to use TCs. In a severe
flare the overall effect of a TC on the skin barrier is positive whereas, before and after a flare,
the effect can be negative and is more likely to exacerbate than improve AD.
P9. Epidermal Abnormalities Underlying Defective Barrier in Netherton Syndrome
Pascal Descargues, Catherine Prost, Sylvie Fraitag, Juliette Mazereeuw, Giovanna
Zambruno, Christine Bodemer, Alain Hovnanian
Inserm U563 and Department of Medical Genetics, Purpan Hospital, BP3028, 31024
Toulouse cedex 3, France, IDI, Rome, Depts of Dermatology and Dermatopathology, Paris
Necker and Toulouse, France
Pascal.Descargues@toulouse.inserm.fr
Netherton syndrome (NS) is a rare autosomal recessive skin disorder characterized by
ichthyosiform erythroderma, hair shaft defect and atopic manifestations with elevated serum
levels of IgE. SPINK5 is the defective gene in NS and encodes the multi-domain serine
protease inhibitor LEKTI, strongly expressed in the granular layer of normal epidermis. The
absence of LEKTI expression in the skin is a constant feature of NS. Significant associations
also exist between polymorphisms in SPINK5 and atopy and/or atopic dermatitis. We have
recently characterized a mouse model for NS and demonstrated that unregulated epidermal
protease activities result in the degradation of desmosomal proteins and the dysfunction of
epidermal barrier. To address whether the degradation of desmosomal cadherins by
unregulated proteases occurred in the epidermis of individuals with NS, we have analyzed
the expression of desmosomal proteins and terminal differentiation markers by immunohis-
tochemistry in the skin of 12 NS patients. Desmoglein-1 was present in the upper spinous
layers but was remarkably reduced in the most differentiated nucleated layers of the
epidermis in 7 patients. Desmocollin-1 and desmoplakin staining was also diminished in 4
patients in these layers. Corneodesmosin expression extended to the upper spinous layer in
3 patients. Involucrin and loricrin expression was enhanced and was redistributed in the most
superficial spinous layers in the majority of cases analyzed. The anomalies of desmosomal
proteins expression were associated with altered desmosome ultrastructure in the upper
living layers of epidermis. Interestingly, there was a redistribution of SCTE immunostaining in
3 NS patients, in the same cellular layers where the expression of desmosomal components
was reduced. Stratum corneum protease activities were increased in NS epidermis in
comparison with controls as shown by in situ zymography. These results show that LEKTI
plays a key role in the control of stratum corneum protease activities to maintain normal
epidermal integrity and to form a functional permeability barrier.
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KL10. Updating The NHS HTA Systematic Review on Evidence-Based Treatments of
Atopic Dermatitis
Hywel Williams
Centre of Evidence-Based Dermatology, Nottingham, UK
hywel.williams@nottingham.ac.uk
The UK National Health Service systematic review of treatments for atopic dermatitis
provided an important milestone in documenting our collective knowledge and areas of
ignorance with regards to the treatment of this important disease. That review was published
in the year 2000, which means that it is already out of date. Although the field of new
randomised controlled trials in atopic dermatitis is moving at a modest rate, it is important to
keep such systematic reviews updated in order for them to be clinically useful. In this talk, I
shall present an update of the 80 or so randomised controlled trials on interventions for the
prevention and treatment of atopic dermatitis that have published over the last 5 years since
the HTA report was published. Since it is impossible to discuss every trial in a short talk, I shall
concentrate on discussing some key developments including (i) probiotics (ii) topical
calcineurin inhibitors (iii) ‘‘weekend’’ therapy for topical corticosteroids (iv) the ETAC study
and (v) the evening primrose oil story. The update of the systematic review of atopic
dermatitis treatments will be published in the public domain in November 2005 at
www.nottingham.ac.uk/dermatology.
1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis.
Health Technol Assess 2000;4(37). Available free online at: http://www.ncchta.org/
execsumm/summ437.htm
IC9. The German Multicenter Trial of Education in Atopic Dermatitis
Thomas Werfel (Hannover/Germany), Doris Staab (Berlin/Germany), Thomas L Diepgen
(Heidelberg/Germany), Manige´ Fartasch (Erlangen/Germany), Jo¨rg Kupfer (Giesen/Ger-
many), Thomas Lob-Corzilius (Osnabru¨k/Germany), Johannes Ring (Mu¨nchen/Germany),
Sibylle Scheewe (Sylt/Germany), Ru¨diger Scheidt (Heidelberg/Germany), Gerhardt Schmid-
Ott (Hannover/Germany), Christina Schnopp (Mu¨nchen/Germany), Ru¨diger Szczepanski
(Osnabru¨ck/Germany), M Wittenmeier Ko¨ln/Germany), Ullrich Wahn (Berlin/Germany), Uwe
Gieler (Giessen/Germany) and the German Atopic Dermatitis Intervention Study (GADIS) Group
Werfel.Thomas@mh-hannover.de
Educational programmes aim to empower patients and/or carers in solving the problems
arising from chronic diseases, and meta-analysis of results has highlighted the need to
develop standardized methodologies so that any improvements in disease self-management
can be more accurately assessed. Although several educational interventions have been
developed for adult AD patients, the literature on educational programmes for children and
their parents is sparse. The German Atopic Intervention Study (GADIS) was set up to develop
standardized interventions for AD self-management, and to address their effects.
Standardized AD group intervention programmes were developed to educate parents of AD
children 3 months to 7 years of age (Group 1); parents and their AD children aged 8–12 years
(Group 2); and AD adolescents aged 13–18 years (Group 3). All patients had a confirmed
diagnosis of AD, and a severity of eczema of at least 20 points on the SCORAD scale. After
randomization to intervention (Group 1, n¼274; Group 2, n¼ 102; Group 3, n¼ 70) or to no
education (Group 1, n¼ 244; Group 2, n¼ 83; Group 3, n¼ 50), parents and/or children in the
intervention groups took part in six, weekly group sessions of 2 hours each. Efficacy was
evaluated using the severity of eczema on the SCORAD scale, and standardized
questionnaires for subjective severity. In programmes for the management of AD in children
under 13 years of age, parental quality of life (QoL) was also assessed. The changes in the
investigated parameters at the beginning of the study (T0) and 12 months after the end of the
education programme (T1) were analysed using analyses of covariance. In all age groups,
significant improvements in SCORAD severity and subjective severity of AD were seen in the
intervention groups, compared with the control groups. Parents of AD children under 7 years
of age experienced significantly better improvement in all five QoL subscales, while parents
of AD children aged 8–12 years experienced significantly better improvement in three of five
QoL subscales. It can be concluded that these educational programmes for the parental
management of AD in children, and self-management of adolescents, improve disease
control and should be integrated into routine care.
OC29. Parental Education in the Long-Term Management in Childhood Atopic Dermatitis
K-B Suhr, Y-S Kim, J-S Yoon, Y-K Kim, M-S Jang, J-H Lee, J-K Park
Department of Dermatology, Chungnam National University, nU Atopy Center, CnU Skin
Hospital, Daejeon, Korea
seokb@cnu.ac.kr
Atopic dermatitis (AD) in childhood is a common inflammatory skin disease with the
prevalence rates increasing. Its chronic course with frequent relapses puts a special burden
on both children and their family. Moreover, in Korea, it is usual that the parents with AD
patients have a low prudential to dermatologic remedy, because they traditionally believe that
taking dermatologic medicine may be toxic to the body. Therefore, in order to maximize
positive long-term outcome in the management of AD, it is important to support parents in
dealing with the chronic condition of their child in addition to treating symptoms. The aim of
this study was to determine the effect of a parental training program on managing AD in
children. Two-hundred fifty seven families participated in this study. They attended weekly on
the 4 educational programs for one month. The subject of each week composed of 1) the
definition and the causes of AD, 2) the medical treatment for AD, 3) the environmental
controls including skin care, and 4) a network therapy for AD. The families were assessed at
the beginning of the study and 6 months later. Main outcome measures: severity of eczema
(SCORAD); treatment behavior; quality of life; and coping strategies. Significant effects were
shown regarding regular bathing and use of moisturizer, use of topical steroids in the event of
exacerbation, and a significant reduction in the use of alternative therapies. Conclusively
speaking, educational programs for parents of children with AD are a helpful adjunct to
dermatological treatment.
OC30. An Audit of the Impact of a Consultation with a Paediatric Dermatology Team on
Quality of Life in Infants with Atopic Eczema and Their Families: Further Validation of the
Infants’ Dermatitis Quality of Life Index and Dermatitis Family Impact Score
P.E. Beattie, M.S. Lewis-Jones
Dept of Dermatology, Ninewells Hospital, Dundee, United Kingdom. DD1 9SY
paula_e_beattie@hotmail.com
Atopic dermatitis [AD] accounts for 10-20% of referrals to secondary care dermatology, often
requiring multiple visits and occupying much valuable time and resources. We audited the
usefulness of two simple and easy to use quality of Life (QoL) measures, the Infants’
Dermatitis Quality of Life index (IDQOL) and Dermatitis Family Impact (DFI), in a routine
clinical setting. The aims were to assess the impact on QoL of AD in infants and their families
and the effect of an initial consultation with a paediatric dermatology team on AD severity and
QoL impairment from the parents’ perspective. The parents of 203 infants (mean age 19.8
months) with AD attending paediatric dermatology clinics completed the DFI and IDQOL. The
parents of 50 of these infants completed both questionnaires before first and second
consultations.
In the 203 children the mean of both the IDQOL and DFI score was 8.47 (median 8 and 7
and SD 5.8 and 6.5, respectively). The IDQOL and DFI correlated well (rs¼ 0.79, 95% CI 0.73-
0.84). The parent’s assessment of the global severity of AD correlated well with the IDQOL
score (rs¼0.60, CI 0.5-0.69) but less well with the DFI (rs¼ 0.4, CI 0.27-0.51). The highest
scoring IDQOL items were itching and scratching, problems at bath-time and time taken to
fall asleep. The highest scoring DFI items were tiredness and exhaustion, sleep and emotional
distress. In both measures these domains also correlated most strongly with eczema severity.
After dermatology consultation the median global severity score rated by 50 parents, fell from
2 (SD 0.83) to 1 (SD 0.8) (CI 0.5-1), the median IDQOL score fell from 8 (SD 5.92) to 5 (SD 5.92)
(CI 2-5.5) and the median DFI score fell from 9.62 (SD 6.45) to 5.49 (SD 6.56) (CI 2-5.5). In 50
infants the mean IDQOL scores for those infants with global AD severity scores of 1, 2 and 3
were 5 (SD 5.65), 8.1 (SD 4.27) and 12.9 (SD 5.67) respectively and improved by 28%, 24%
and 49% respectively while the mean DFI scores by 40%, 35% and 50% respectively. The
most improved IDQOL items were the time taken to get off to sleep and difficulty at mealtimes
and the most improved DFI domains were tiredness and exhaustion and emotional distress in
the parents.
We have provided further important information on the effects of AD on infants and their
families using the IDQOL and DFI QoL measures. We demonstrate the usefulness of these
measures in routine clinical management of AD and show the beneficial effect for both infants
and parents of the initial consultation by a dermatology team in a secondary care setting.
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OC31. Comparative Trial of Topical Corticosteroids in Atopic Dermatitis
T Uenishi1, H Sugiura1, T Tanaka1, M Uehara2
(1) Department of Dermatology, Shiga university of Medical Science, Otsu, Japan, (2) Yasu
hospital, Yasu, Japan
uenishi@belle.shiga-med.ac.jp
Background: Application of topical corticosteroid is a basic treatment in the management of
atopic dermatitis. In Japan, topical corticosteroids are separated into five classes based on
potency. Class 1 includes the most potent, while class 5 includes the least potent and
Japanese dermatologists are recommended that they should use topical corticosteroids with
appropriate potency according to the severity of the skin lesions. However, it is not clear that
topical corticosteroids with the same potency are equally effective in ameliorating skin
lesions of atopic dermatitis. Moreover, it remains to be determined whether clinical
effectiveness of topical corticosteroid closely parallels the potency of the agent. In the
present study, therefore, we performed comparative trial of topical corticosteroids in patients
with atopic dermatitis.
Methods: A total of 1424 patients with atopic dermatitis were included in the study. Patients
were instructed to apply one topical corticosteroid on the right side of the trunk and another
topical corticosteroid on the left side of the trunk. Potencies of two topical corticosteroids
were equal in 1212 patients (class 1 in 28 patients, class 2 in 682 patients, class 3 in 480
patients, class 4 in 22 patients), while potencies of two topical corticosteroids were different
in 212 patients (class 1 vs class 2 in 12 patients, class 2 vs class 3 in 122 patients, class 3 vs
class 4 in 78 patients). A week later we checked their skin condition to compare the clinical
effectiveness of one topical corticosteroid with that of another topical corticosteroid. The skin
condition was assessed on a five-point scale: markedly improved (450% improvement),
moderately improved (25% to 50% improvement), slightly improved (o25% improvement),
unchanged or worsened. When skin lesion of one side markedly improved and skin lesion of
another side slightly improved, unchanged or worsened, the clinical effectiveness of 2 kinds
of topical corticosteroids were judged to be different.
Results: The clinical effectiveness of 2 kinds of topical corticosteroids were different in 210
(15%) of the 1424 patients examined. Topical corticosteroids with the same potency showed
different clinical effectiveness in 117 (10%) of the 1212 patients, while topical corticosteroids
with different potencies revealed different clinical effectiveness in 93 (44%) of the 212
patients. The topical corticosteroids with less potency showed more remarkable improve-
ment than that with more potency in 32 (34%) of the 93 patients.
Conclusion: This study suggests that comparative application of topical corticosteroids is a
useful way to find appropriate agents in the management of atopic dermatitis.
P10. Atopic Dermatitis and Cancer Risk
Hao Wang & Thomas L. Diepgen
University Hospital Heidelberg, Dept. of Social Medicine, Occupational and Environmental
Dermatology, Germany
Background: Epidemiological studies have provided growing evidence of a link between
atopy and cancer risk.
Objective: The aim of this paper is to review the evidence from case-control studies and
cohort studies on a possible association between atopic dermatitis (AD) and cancer risk, with
particular attention to the case-definition of AD.
Methods: Studies with quantitative data on the association between AD (eczematous
disease) and cancer risk were obtained from MEDLINE in combination with a review of cited
references.
Results: In 23 publications, AD has been implicated in the risk of haematologic (childhood
leukaemia (n¼ 3), adult leukaemia (n¼ 3), non-Hodgkin lymphoma (NHL) (n¼ 4) and different
haematological cancers (n¼ 1)), pancreatic (n¼ 5), skin (n¼ 2) and brain malignancies (n¼ 5).
The overall picture of the results of these studies shows that a history of AD may be
associated with a decreased risk of pancreatic cancer, brain tumour and childhood
leukaemia, although in most instances the findings were not statistically significant. No
consistent associations were observed for skin cancer or Non-Hodgkin’s Lymphoma. The
definition of AD had varying quality, and was imprecise in many publications.
Conclusions: The findings of the epidemiological studies tend to support a lower risk of
cancer among persons with a history of AD. Although a more careful definition of AD is
needed, these epidemiological studies could provide an estimate of the background cancer
risk in patients with AD when the long-term effects of treatments for AD are assessed (e.g., for
topical immunomodulators).
P11. Methotrexate Treatment of Atopic Dermatitis
Goujon C., Saad N., Guillot I, Hennino A., Be´rard F., Nicolas JF
Centre Hospitalier Lyon Sud 69 495 Pierre- Be´nite
catherine.goujon@chu-lyon.fr
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by
allergen-specific, type 1 and 2 cytokine-producing Tcells which are recruited and activated in
lesional skin. The therapies available for moderate to severe AD include topical agents
(corticosteroids, immunomodulators) and systemic drugs (phototherapy, cyclosporin).
Methotrexate is an old systemic agent used at low dosage for the treatment of psoriasis,
another Tcell-mediated skin disorder. The side effects are well-known, infrequent and in most
cases not severe. More importantly, recent studies showed that MTX does not have broad
immunosuppressive properties and behaves more as an anti-inflammatory molecule at the
low doses used in dermatology. Indeed, MTX selectively targets activated T cells and has no
effect on naı¨ve and memory T cells. Therefore, we postulated that MTX could be a valuable
and safe treatment of AD.
Study design: In the present open retrospective study, we show that low-dose MTX is an
effective treatment of adult AD. Twenty patients (17 to 68 years old) with mild to severe AD
and unresponsive to routine therapies were treated (three months to 2 years) with a weekly
dose of MTX ranging from 7.5 to 25 mg, i.e. using the same protocol as that used in psoriasis.
Laboratory tests were performed before treatment and every two weeks during the first three
months and monthly thereafter (complete blood count, serum creatinine, aspartate
aminotransferase, alanine aminotransferase).
Results: 75% of patients improved after 3 months of MTX use. The beginning of
improvement was observed between the fourth and the sixth week after MTX was initiated.
At 3 months, the improvement, based on physician global assessment and patient’s
evaluation of pruritus and quality of life, was 470% in 15/20 patients. MTX was stopped for
three reasons: a high cumulative dose 41.5 g, dramatic improvement of AD and opportunity
to start another treatment e.g. tacrolimus. Adverse events were nausea, hepatitis cytolysis
with mild intensity. Side effects affected 6 patients and required discontinuation of MTX for 3
patients.
Discussion: From this open study, MTX could be considered as an effective and safe
treatment of AD. Our study confirms the few previous reports of the efficacy of MTX in
eczema (Egan et al.; Shaffrali et al). Controlled studies comparing MTX and placebo and MTX
and cyclosporine are ongoing.
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0C32. Atopic Eczema and Malassezia
Annika Scheynius
Department of Medicine, Clinical Allergy Research Unit, Karolinska Institutet and University
Hospital, Stockholm, Sweden
The predominant allergic condition is atopic eczema (AE) with a prevalence of up to 20%
among children and young adults in many parts of the world. Pathogenesis of AE is likely to
result from defects in the immune system and a defective skin barrier, with both genetic and
environmental factors contributing. Interestingly, microorganisms have been demonstrated
not only to cause skin infections but also to trigger allergic symptoms by acting as allergens.
One such microorganism is the yeast Malassezia formerly known as Pityrosporum which
belongs to our normal cutaneous microflora but can cause skin infections and even systemic
infections. Malassezia species are lipophilic yeasts commonly found on the body surface in
humans and warm blooded animals. Several studies have shown that specific IgE and/or T-
cell reactivity to Malassezia can be detected in a majority of adult patients with AE, and that
antifungal treatment ameliorates the eczema and lowers the serum IgE levels (Scheynius A.
et al Int Arch Allergy Immunol 2002;127: 161–9). We have therefore chosen M. sympodialis,
the most common species isolated on skin both from healthy individuals and patients with
AE, as a model for studies on host-microbe interactions to deepen our understanding of how
a member of the normal skin flora can interact with the innate and adaptive immune system
and contribute to the pathogenesis of AE. We have preliminary data indicating that the release
of M. sympodialis allergens is significantly higher at pH 6, reflecting the higher pH in skin of
patients with AE than that at pH 5 (normal skin pH). These data suggest that the skin barrier in
AE patients provides an environment that can enhance the release of allergens from M.
sympodialis, which can contribute to the perpetuation of the inflammation. So far we have
successfully cloned, sequenced and characterized nine M. sympodialis-derived allergens,
designated Mala s 1 and Mala s 5 - 12. Four of our identified M. sympodialis allergens are
without homology to known proteins, while the others have potential cross-reactivity to
human homologues like stress-induced heat shock proteins (HSP) and manganese super-
oxide dismutase (MnSOD). We now have a unique opportunity to dissect pathogenic
mechanisms in AE in relation to cross-reactivity with endogenous structures with the
hypothesis that by molecular mimicry environmental fungal allergens might induce
autoimmune reactivity to endogenous proteins. Obtained results will help clarifying whether
Malassezia allergens can break immunologic tolerance possibly leading to an autoimmune
response in AE. With our recombinant M. sympodialis allergens, we have created unique tools
that have improved the diagnosis of AE using diagnostic tests like SPT and serology for
detection of IgE-mediated reactivity. We have also developed an atopy patch test (APT)
method and an in vitro lymphocyte proliferation assay to detect T cell-mediated reactivity
against M. sympodialis. Interestingly, with our diagnostic tools we have found IgE-mediated
sensitization against M. sympodialis in patients with the so called ‘‘intrinsic’’ form of AE, also
denoted ‘‘non-atopic eczema’’. These patients present similar clinical symptoms but the
underlying pathogenic mechanisms seem to differ. It is important to recognize the different
subgroups of AE patients in order to identify underlying disease mechanisms and to offer the
patients proper advice and treatment. We will now continue to improve the diagnostic
methods to identify different subgroups of AE patients and to dissect underlying pathogenic
mechanisms with the help of our unique recombinant allergens.
OC33. Studies with Aeroallergen Atopy Patch Tests
U Darsow, J Ring
Dept. of Dermatology and Allergy Biederstein, Technical University Munich, Division of
Environmental Dermatology and Allergy GSF/TUM, Munich, Germany
Although IgE-mediated sensitizations to aeroallergens demonstrated by skin prick tests (SPT)
or in vitro measurement of specific IgE-antibodies (sIgE) are very frequent in patients with
atopic eczema (AE), these routine tests show a low specificity for clinically relevant allergy.
For aeroallergens, more specific results can be obtained with the atopy patch test (APT).
In a European multicenter study on APT in 324 patients and controls using the ETFAD
methods, positive aeroallergen APT reactions were seen in 10–39% (mostly to D.
pteronyssinus) of patients, none in controls. Positive SPT (44–57%) and elevated sIgE (46–
59%) were more frequent. Depending on the allergen, 20–34% of patients had a predictive
history. 7–17% of patients had a clear-cut positive APTwithout positive SPT or elevated sIgE.
Two of these patients with a corresponding history of AE triggered by house dust contact and
with a positive APT to D. pteronyssinus showed sIgG4 against Der p 3. With regard to an
aeroallergen-specific history, APT specificity ranged from 64–91%.
Currently, the APT is also used as inflammation model in trials on pathophysiology and
topical and systemic therapy of AE. Such studies showed that APT reactions can be
enhanced in volunteers after exposure to volatile organic compounds and can be modulated
by pretreatment with pimecrolimus.
Aeroallergens can elicit eczematous skin lesions in patients with AE, also without
corresponding sIgE. APT can be used to evaluate the clinical relevance with high specificity,
the combination with SPT and sIgE is recommended.
OC34. Food Atopy Patch Test and Repeated Food Challenge
S. Seidenari, F. Giusti
Department of Dermatology, University of Modena and Reggio Emilia, Italy
seidenari.stefania@unimo.it
Food hypersensitivity is a common medical problem in atopic dermatitis (AD) patients, mainly
in paediatric age. Patch tests based on prolonged exposure of the skin to food, aiming at the
detection of delayed reactions, represent a testing modality reproducing skin responses
against allergens normally occurring in AD. Atopy patch tests (APTs) have been demonstrated
to improve the accuracy of skin testing in the diagnosis of food allergy in AD patients;
whereas immediate-type reactions proved to be associated with skin prick test positivity, APT
reactivity is more frequently observed in patients with delayed responses. Relevance of
positive and negative APT responses should be assessed by food challenge results.
Double-blind placebo-controlled food challenge (DBPCFC) is considered the gold standard
for diagnosing food allergy, however, besides the fact that there is no universally accepted
standard for performing the DBPCFC, these testing and observation modalities may not
identify the whole spectrum of skin reactions possibly appearing in AD patients after food
ingestion, which encompasses both prompt and eczematous responses sometimes
appearing more than 48 hours after the challenge and requiring repeated administration of
the foodstuff. Since many authors demonstrated that an open challenge associated to careful
follow-up can prove adequate in identifying food allergic patients, also enabling the diagnosis
of delayed reactions, the repeated open food challenge (ROFC) may be considered a useful
and practical alternative to DBPCFCs.
In our experience this challenge modality seems to be well accepted and enables a good
compliance. The subjects undergoing challenge are given a dose of the suspected food
reflecting the normal intake daily at home for a week. The first administration is performed at
the hospital in selected cases, depending on the nature and severity of the reaction to food
allergens. When a clinical reaction is noted, the test is stopped and the patient is examined at
the hospital. All subjects are examined on day 7 of the challenge.
APTs with egg, cow’s milk and peanut were performed in 222 AD subjects undergoing
repeated open challenges. 11%, 9% and 22% of them reacted to APT with egg, milk and
peanut, respectively. Whereas sensitivity figures were low (31% for egg, 15% for cow’s milk,
and 37% for peanut), specificity was high (79% for egg, 92% for cow’s milk, and 77% for
peanut), indicating that a positive patch test enables the identification of food-allergic
subjects.
OC35. SAFT and APT Using Fresh Foods in Children with Atopic Dermatitis and Food
Allergy
Arnold P. Oranje, Arjan C. A. Devillers, P.G. Mulder, F.B. de Waard-van der Spek
Erasmus MC Rotterdam, the Netherlands
arnold.p.oranje@inter.nl.net
Atopic dermatitis [AD] is a chronic relapsing skin disease, usually beginning in infancy. AD is a
multifactorial disease and several triggers have been recognized. Food allergy plays a role in
a subgroup of infantile AD. A correct diagnosis of food allergy [FA] therefore is important to
identify these children. Testing of FA is complicated and none of the current tests is
completely decisive. In children with AD we perform allergological tests when they are
suspected from food allergy. Most skin tests are based on the lgE-mediated type I
hypersensitivity reaction. We perform the Skin Application Food Test (SAFT), according to
Oranje, in children till the age of 3 years. This test is based on the mechanism of the ‘contact
urticaria syndrome’ [CUS]. The food, in the way it is consumed, is put on the aluminum cup of
a Finn Chamber on Scanpor tape. The test scores almost equal to an oral challenge. In
children, older than 3 years, we prefer the prick-prick test. A small lancet is used to ‘prick’ in
fresh food allergens, with a second ‘prick’ in the skin of the volar surface of the arm. Next to
tests such as SAFT (skin application food test) and prick-prick test with fresh food, we also
perform APT (atopy patch test) in SAFT-negative patients. Final proof will be obtained by the
double-blind, placebo-controlled food challenge (DBPCOC), but in children younger than 2
years an open challenge is performed. The DBPCOC is considered the gold standard for
diagnosing food allergy, but lacks exact definitions and therefore breakpoints. We found that
the SAFT is equivalent to the oral challenge in children aged less than 3 years. The APT results
only add a limited number of food allergic patients/cases.
de Waard-van der Spek FB, Elst EF, Mulder PG, Munte K, Devillers AC, Oranje AP.
Diagnostic tests in children with atopic dermatitis and food allergy. Allergy. 1998;53:1087-91.
Devillers AC, Waard-van der Spek, de FB, Mulder PG, Oranje AP. Atopy Patch Test and
SAFT as diagnostic tools in young children with atopic dermatitis and suspicion of food
allergy. (in preparation)
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OC36. Atopy Patch Test with Foods
Kristiina Turjanmaa
Department of Dermatology, Tampere University Hospital, Tampere, Finland
kristiina.turjanmaa@uta.fi
Atopy patch test (APT) has received much interest in recent years as a model for studying
pathomechanism of atopic dermatitis (AD) and as a complementary test for diagnosing
protein allergens causing or maintaining AD either by airborne contact or by food. From the
time when the name of APT was given by Ring et al.in 1989 epicutaneous tests have been
performed with allergens known to elicit IgE-mediated immediate reactions with the same
allergen. Later a small subgroup of patients with AD has been identified to show positive APT
with no positive circulating specific IgE to the same allergen. Even if the mechanism behind
this reaction type is not totally clarified it opens new possibilities especially in the diagnosis of
children with AE and food allergies but no specific IgEs.
The methodology of epicutaneous testing with aeroallergens and standardization of test
materials has been extensively worked out in recent years by the group of Darsow and Ring
(2000), but the standardization of APTs with foods still needs much work before it can be
recommended for routine clinical diagnosis. In contrast to aeroallergens the sensitivity and
specificity of APT in diagnose of food allergy can be calculated in relationship to challenge
test with the same food. Unfortunately the challenge test itself is not exhaustively
standardized.
For methodological aspects a 48 h occlusion time with readings at 48 h and 72 h seems
convincing with foods, the skin of back is the best place for applying APT, and the APTseems
to be fairly reproducible. There are no commercially available APT materials with foods so far.
Well-planned multicenter studies are needed. The same is true for the reading of test
reactions. Erythema with infiltration is regarded as minimal requirement for positive APT, but
the role of the number of papules is not yet clear. In different papers different vehicles and
control materials are used, some authors use tape stripping, others none. By the time being
there are already more healthy controls tested with APT, but more studies in different age
groups are needed. Adverse effects with APT are mild and include local flares with itching,
contact urticaria, irritation from adhesive tapes. No active sensitisation has been reported
with foods. There is no final agreement whether APTs with foods are equally practicable in
different age groups.
There are several studies reporting sensitivity and specificity of APT for cow’s milk, egg,
and wheat. Even if the numbers vary the sensitivity for APT is mostly better than for skin prick
test (SPT) but the specificities tend to be higher for SPT. The values need to be studied in
multicenter studies with large patient material at the same age and with the same procedure
for food challenge test.
At the time being food challenge test still remains the gold standard for diagnosing food
allergy. The clinical picture of food allergy has changed and relatively simple cases with
‘‘only’’ milk and egg allergies have become rare, the modern picture of food allergy is multi-
allergy. Multiple double blind placebo controlled food challenges cause stress to children and
their parents as well as to the society in form of high costs. Therefore development of new
additional tests is indicated for the accurate diagnose of food allergy and APT seems to be
promising.
OC37. The Geneva Experience with Epicutaneous Tests 2000–2005 in Atopic Children
J. Lu¨bbe, A. Gkomouzas, A-M Calza
Dermatology clinic, University Hospital, Geneva, Switzerland
Jann.Lubbe@hcuge.ch
Background: Corneotherapy is a baseline therapeutic approach in children with atopic
dermatitis. Almost all available emollients contain preservatives, and many contain
fragrances. Atopic dermatitis patients are characterized by a defective skin barrier and
may thus be at a higher risk to develop contact sensitization to topical treatments.
Objective: To compare the frequencies of positive epicutaneous patch tests in atopic vs.
non-atopic children.
Methods: Retrospective analysis of patch test results in children up to 15 years that were
tested to both standard and preservatives series allergens since 2000 in two Geneva
outpatient facilities. Analysis of patient files was completed by telephone interviews in the
case of imprecise information about presence of atopic diathesis, i.e. past or present atopic
dermatitis, atopic asthma, or rhinoconjunctivitis.
Results: A total of 56 children were identified that had presented one or several positive
reactions to epicutaneous patch tests with both standard and preservative series. 43 children
were atopic, 13 were non-atopic. 27/43 atopic patients were sensitized to one or several
preservatives, as compared to only 1 of 13 non-atopic patients.
Conclusion: Children with atopic diathesis are more often sensitized to preservatives, than
non-atopic children. This may reflect higher exposition because of intensive use of emollients,
or because of the defective skin barrier. Prospective studies are needed in order to establish
the causative pertinence of positive sensitizations to preservatives in atopic patients.
OC38. The Labial Food Challenge in Children with Atopic Eczema
Fabienne Rance´
Hoˆpital des Enfants, CHU Toulouse Purpan, France
rance.f@chu-toulouse.fr
Atopic eczema is common in infants. In population based studies a cumulative prevalence of
atopic dermatitis (AD) in childhood around 15-20% has been reported (1). Patients with atopic
eczema have a strong systemic allergic response associated with marked elevations in serum
IgE, activated eosinophils, and T cells. Food allergies play an important role in the
pathogenesis of atopic eczema, affecting approximately one third of children with atopic
eczema (1). Detection of these patients and identification of the offending foods will lead to
marked improvement of the morbidity of AE.
Suspected food allergy should be confirmed using appropriate diagnostic tests (2). Skin
Prick Testing and measurement of serum specific IgE will demonstrate sensitisation to the
offending food. In case of delayed hypersensitivity atopy patch testing (APT) might be
informative. Specific elimination diets implemented over a one to six week period may help
identify trigger foods which are not immediately apparent. Examining children with atopic
eczema, the ‘‘gold standard’’ in food allergy diagnosis is the double-blind placebo controlled
food challenge (DBPCFC); however the procedure is time consuming, therefore expensive
and poses a potential risk to the patient. Food challenges should only be performed by well-
trained physicians in medical settings allowing management of anaphylactic reactions.
Labial food challenge (LFC) should be performed as the first step of an oral food challenge
(3). It involves contact between the food and the labial mucosa, to test for local cutaneous
manifestations. The anatomic characteristics of the lip make it suitable for allergy testing. The
labial epithelium differs on different parts of the lip, and there is little keratinization outside the
mouth and none inside and thus permeability is slight. The lip is red because of the rich
vascularization of the chorion, which leads to even minor histamine type vasodilation causing
visible edema. Finally, the labial mucosa contains mastocytes, which in the presence of even
small amounts of allergen, are able to degranulate and release histamine and inflammatory
mediators. This approach tends to avoid systemic reactions. The manifestations result from a
local expression of the IgE response to the antigen. This technique can use both commercial
extrats and crushed fresh food resuspended in physiological salt solution. A drop was placed
on the lower lip and left for 2 minutes with the mouth slightly opened with a cotton swab
between the lip and gum. The result was read 15 minutes later. Positive reactions in LFC can
be divided into five types: 1) smoothing on the lower lip; 2) erythema under the lip; 3) edema
of the cheek associated with rhinitis and watering eyes; and 5) systemic reaction associated
with itching of the areas affected by eczema and coughing.
The LFC has several advantages. It is straightforward and takes less than 30 minutes. Only
a single dose is required. Outpatients can be tested, at the same time as undergoing skin
prick tests. The risk of systemic reactions is lower than that associated with the oral food
challenge (3). The major drawback of the LFC is the difficulty in detecting weak reactions. The
relatively poor sensitivity of the method requires oral food challenge after negative LFC
results.
1. Host A, Andrae S, Charkin S et al. Allergy testing in children : why, who, when and how ?
Allergy 2003 ; 58 : 559–69.
2. Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004 ; 113 : 805–19.
3. Rance´ F, Dutau G. Labial food challenge in children with food allergy. Pediatr Allergy
Immunol 1997 ; 8 : 41–44.
P12. Is The Labial Food Challenge a Useful Tool in the Management of Food Allergy in
Children with Atopic Dermatitis?
Franck Boralevi, Thomas Hubiche, Sylvie Roul, Christine Le´aute´ Labre`ze, Alain Taı¨eb
Pediatric Dermatology Unit, Children University Hospital of Bordeaux, France
franck.boralevi@chu-bordeaux.fr
The overall prevalence of food allergy in young children under 3 years is estimated between 4
8%, and this prevalence being higher in atopic dermatitis (AD) children. The usual diagnosis
of food allergy is made with skin prick testing and specific serum IgE assay followed by an
oral food challenge (OFC). Recently, labial food challenge (LFC) was introduced as new
diagnostic tool for food allergy (1). The objective of this study was to carry out a prospective
comparison of OFC and LFC results regarding three common food allergens.
Patients and methods: We enrolled all the AD children with a suspected egg, peanut and/or
cow’s milk allergy referred to us for an OFC, from June 2001 to January 2005. After
examination of the food allergy history, appropriate skin prick testing and specific IgE assays,
LFC was performed immediately before OFC in a day hospital. Anti histamines were stopped
at least 7 days before the tests. LFC were performed using a drop of commercial food extract
of egg or peanut (Stallerge`ne, France) or fresh milk put on the lower lip and left 10 seconds.
The result was obtained 15 minutes later and positive reactions, mostly labial edema with or
without contiguous urticaria, were graduated from 1 to 5 as previously described (1). OFC
were then performed as single blinded tests using placebo and allergen extract capsules
(Lofarma, Italy), followed by an open challenge with the concerned food, i.e. one egg, 3
peanuts or 150 ml of milk.
Results: An overall of 426 AD children (248 boys, 158 girls, aged from 1 to 12, mean age 4.02
years) were enrolled. Children were referred for egg, peanuts or milk allergy respectively in
228, 147 and 51 cases. LFC was positive in 110 cases and OFC in 136 cases, manifesting as
urticaria (94), gastro-intestinal manifestations (75), asthma (29) and flare-up of eczema (15).
Compared to the results of OFC, considered as the standard reference, the positive
predictive value of LFC was 0.55, and the negative predictive value was 0.77. No difference
was found between the three groups of food allergens. LFC caused systemic reactions in 2
cases (0.4%).
Conclusion: LFC is a simple and rapid to perform test in outpatients AD children, and it has
been progressively and widely used in French allergist offices since the paper published by
Rance´ & coll. (1). Nevertheless, its predictive values and sensitivity are poor in AD children.
We thus consider that it is premature to use the LFC as a substitute of OFC, but further
studies are needed to investigate LFC as a part of a score including the results of skin-prick
test and/or specific IgE assays.
References
1. Rance´ F, Dutau G. Labial food challenge in children with food allergy. Pediatr Allergy
Immunol 1997: 8: 41–44.
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P13. The Comparison of Atopy Patch Test with Skin Prick Test in Korean Patients with
Atopic Dermatitis
K-B Suhr, Y-S Kim, J-S Yoon, E-J Oh, E-H Lee, J-H Lee, J-K Park
Department of Dermatology, Chungnam National University, CnU Atopy Center, CnU Skin
Hospital, Daejeon, Korea
seokb@cnu.ac.kr
Atopic dermatitis (AD) in childhood is frequently associated with food allergy. Allergic
phenomena to food may be a consequence of both IgE- and non-IgE-mediated reactions.
IgE-mediated mechanism can be evaluated by the skin prick test (SPT), while non-IgE
mediated allergic responses by the atopy patch test (APT). Our aim was to investigate APT
and SPT results to food allergens in 85 Korean with AD, and to further evaluate their relevance
by performing repeated open challenges with positive food allergens. Eighty five patients
suffering from AD and suspected food-related clinical symptoms were investigated with APT
and SPT. The candidate food allergens were 30 kinds of plant or animal food. Of 40 APTs, egg
white (39%), baker yeast (31%), cow milk (27%), beef (27%), chicken (27%), soybean (23%)
were positive in order. Out of below 5 years with AD, egg white, beef, soybean, and cow milk
were frequent in order, while, among above 6 years, egg white, egg yolk, pork, and baker
yeast in order. When the SPT was performed in 45 ADs, baker yeast (47%), cow milk (30%),
soybean (20%), and egg white (17%) were positive in frequency. Cow milk, soybean, egg
white, and garlic were main positive allergen among below 5 years of ADs, while baker yeast,
tuna, and soybean were positive allergen in order among above 6 years of ADs. In a
meantime, we are performing open food challenges with positive allergens to confirm the
relevance with APT or SPT, and will further present the results at the ISAD meeting.
P14. Gene Expression Change of PBMC using IGEC (Immune Gene Expression Chip) by
Milk Stimulation Test in Milk Allergy of Atopic Dermatitis
GeunWoong Noh, Sooyon Choi
Seoul Allergy Research Institute, Food BioTech. Co. Ltd, Korea
admyth@naver.com
There is no convicing test for the diagnosis of food allergy except oral food challege test.
IGEC (Immune Gene Expression Chip) was developed for the analysis of Gene expression.
Gene expression change of PBMC by in-vitro milk stimulation using IGEC. A total of 50 Atopic
dermatitis patients with or without milk allergy participated in this study. PBMCs were
separated and stimulated with crude milk protein extract. The expression of 20 genes of
cytokine, cytokine receptor and the gene for the intracellular signal transduction were
evaluated. Gene expressions of PBMC were changed by milk stimulation. Characteristically,
the gene expressions of STAT 1, STAT4 and CD40 Ligand were decreased in atopic dermatitis
patients with milk allergy as compared to those without milk allergy. Conclusively, gene
expression profile representative for food allergy were analyzed using IGEC, the gene
expression DNA Chip in this study.
P15. Follow-Up Study of 92 Infants with Multiple Food Allergies
Kristiina Turjanmaa, Anna-Riina Ketvell
Dept of Dermatology, Tampere University Hospital, Finland
kristiina.turjanmaa@uta.fi
Ninety-two infantso1 year of age (mean 6.1þ /-2.4 months) with atopic dermatitis (AD) and/
or gastro-intestinal (g-i) symptoms were examined for the first time at our Allergy Unit. Skin
prick tests (SPT) with large number of foods were performed in all of them and atopy patch
tests (APT) with cow’s milk (CM), egg, soy and cereals in 82 infants. Challenge tests were
performed with CM and wheat. Sixteen infants needed only minor elimination guidelines and
were followed-up at the well-baby clinics whereas 76 children were followed-up until the age
of two years at the University Hospital. The outcome of symptoms with elimination of foods
causing symptoms was recorded retrospectively.
Thirty-three children showed positive and 31 children negative reaction to open CM
challenge. Sensitivity of SPT to CM was 0.30 and specificity 0.87 whereas the respective
numbers with APT were 0.61 and 0.57. Open wheat challenge was positive in 19 and
negastive in 26 children. Sensitivity for SPT was 0.47 and specificity 0.80, the corresponding
numbers for APT were 0.82 and 0.17. In other children and with other foods the challenges
were done at home and the patients were followed regularly and the allowed foods were
recorded at every visit on a special form. The follow-up results are given for egg, CM and
wheat, but several other foods were eliminated at the same time based on home challenges
and compensated by suitable foods to guarantee normal growth.
At the age of 1/2 year(s) 10/8 children avoided egg, 2/1 children CM, 8/5 egg and CM, 25/
16 egg and wheat (includes elimination of rye, barley and often oat), and 29/11 children egg,
CM and wheat, respectively. Thirty-nine/54 children were asymptomatic at the age of 1/2
year(s). Careful diagnosis and elimination of culprit foods seems to be an adequate therapy
and it is well accepted by the families.
P16. Alternaria Alternata Patch Tests on a Study Population of 500 Atopic Dermatitis
Patients
F. Giusti, S. Seidenari
Department of Dermatology, University of Modena and Reggio Emilia, Italy
giusti.francesca@unimo.it
Introduction: Literature data on clinical symptoms related to exposure to Alternaria
Alternata mostly concern subjects with respiratory atopy, whereas its role in the pathogenesis
of atopic dermatitis (AD) has been poorly investigated. The aim of this study was to
investigate Alternaria Alternata patch test results and to correlate the results to clinical history
and specific IgE.
Methods: 500 patients with atopic dermatitis (AD), 222 males and 278 females, underwent
patch testing with Alternaria Alternata 2.4% in petrolatum, provided by Lofarma (Milano,
Italy). Specific IgE to Alternaria Alternata were detected by prick tests (Stallergenes, France).
Results: 38 (7,6%) patients, 13 males and 25 females, proved positive to Alternaria Alternata
patch test. Among them, 12 subjects were affected by rhinitis and/or asthma. The most
frequently involved skin sites in AD patients sensitised to Alternaria Alternata were the face,
the flexural areas of the limbs and the neck. Among patients undergoing skin testing, 64
(12,8%) reacted to Alternaria Alternata prick tests.
Discussion: The significance of positive patch test responses to Alternaria Alternata patch
tests remains questionable. The possibility that molds may be involved in the development of
skin lesions in patch test-positive AD patients, should be checked with specific provocation
and elimination procedures, which is particularly difficult, owing to the multifactorial etiology
of AD.
P17. Allergic Sensitization to Common Inhalant Allergens and the Association with
Atopic Diseases: Results of a Population Based in Elderly
M. Wolkewitz1, D. Rothenbacher2, M. Lo¨w2, C. Stegmaier3, H. Ziegler3, H. Wang1, H.
Brenner2, and T.L. Diepgen1
1Department of Clinical Social Medicine at the Ruprecht-Karls-University Heidelberg,
Germany; 2The German Centre for Research on Ageing at the Ruprecht-Karls-University
Heidelberg, Germany; 3Unit for Health Monitoring, Saarland Ministry for Public Health,
Germany
Thomas.Diepgen@med.uni-heidelberg.de
Background: There is a lack of epidemiological studies of atopic dermatitis and allergies in
the elderly.
Objectives: To determine the prevalence of allergic sensitisation to common inhalant
allergens and describe the main socio-demographic determinants of allergic sensitisation
in a large population based sample of elderly. In addition we investigated the association of
allergic sensitisation with the prevalence of physician diagnosed atopic dermatitis, hay fever,
and asthma in individuals older than 50 years.
Methods: 4696 participants aged 50 to 74 years were recruited in the State of Saarland,
Germany. All subjects filled out a standardized questionnaire and reported whether a
physician had diagnosed atopic dermatitis, hay fever, or asthma. The presence or absence of
specific IgE to common inhalants, like mite, oak, ragweed, grass, dog, cat and alternaria, was
determined in the serum samples of all participants.
Results: Overall, we found a prevalence of 21.2% for allergic sensitization in the study
population (mean age 61.9 years (SD¼ 6.6)). The prevalence was 24.4% in males and 18.7%
in females, decreased with increasing age (p trendo.0001). Urban living in adolescence, a
longer duration of school education and having a family history of atopy were associated with
an increased risk for allergic sensitization. The prevalence of self-reported atopic dermatitis,
hay fever, and asthma was 4.1%, 28.7%, and 10.8% among those with positive IgE response
and 3.7%, 2.7%, and 4.0% in those without an IgE response.
Conclusion: The prevalence of allergic sensitization to inhalants appeared lower in the elderly
compared to studies among younger adults. Even in our age group the prevalence decreased
with increasing age. Sensitization to inhalants was associated with a high prevalence of
respiratory symptoms such as hay fever and asthma but not atopic dermatitis in the elderly.
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KL11. Treatment of Atopic Dermatitis from a Skin Barrier Perspective
Michael J Cork, Darren A Robinson, Yiannis Vasilopoulos, Adam Ferguson, Manar
Moustafa, Rachid Tazi-Ahnini and Simon J Ward
Dermatology-Biomedical Genetics, University of Sheffield Medical School, Sheffield, UK
There is increasing awareness that breakdown of the skin barrier may be one of the primary
events in the development of atopic dermatitis. A recent systematic review of IgE
measurements in children with atopic dermatitis revealed that in community studies up to
66% of the children did not have a raised IgE (specific or non-specific) at the point of
sampling.1 These children with mild moderate intrinsic atopic dermatitis can be regarded as
having a primary transitory form of the disease.2 One suggestion has been that there could be
a primary defect in the skin barrier in atopic dermatitis3 and this could be part of the
explanation for intrinsic ‘atopic’ dermatitis.
The barrier to the penetration of irritants and allergens into the skin is located in the stratum
corneum. Corneodesmosomes lock the corneocytes together and prevent them being
dislodged by shearing forces. Corneocytes are shed from the surface of the skin by
proteolysis, which is mediated by skin specific proteases, such as stratum corneum
chymotryptic enzyme (SCCE). These proteases are inhibited by skin-specific protease
inhibitors, such as secretory leukocyte protease inhibitor (SLPI). It is essential that premature
desquamation and a breakdown of the skin barrier is prevented. A breakdown/thinning of the
stratum corneum permits the penetration of irritants and allergens, which in turn can lead to
the development of flares of atopic dermatitis.
In children with intrinsic atopic dermatitis, a strong genetic association has been
demonstrated with an AACC insertion in the 3’UTR of the SCCE gene.4 The most likely
consequence of this insertion is to increase the levels of SCCE protein in the skin, leading to
enhanced breakdown of the skin barrier and allowing the penetration of irritants and
allergens, leading to a flare of atopic dermatitis.4 Within a severe flare of atopic dermatitis
there are also high levels of secondary and exogenous proteases which further enhance
breakdown of the skin barrier.
The skin protease SCCE exhibits a neutral pH optima.5 A change from pH 7.5 to 5.5
reduces SCCE activity by 50%.6 The normal pH of the skin is 5.5, but washing with soap or
detergents has been shown to raise the pH to 7.5 or more. Therefore, soap and detergents
can cause a reduction in the thickness of the stratum corneum and induce flares of atopic
dermatitis. Some emollients contain surfactants which have been associated with a large
number of cutaneous reactions. Topical corticosteroids can cause a thinning of the stratum
corneum as a result of damage to corneodesmosomes.7,8 This effect appears to be
mediated, at least in part, by the induction of skin proteases such as SCCE.7
The new understanding of the central role of skin barrier dysfunction in atopic dermatitis
provides both an opportunity to develop new products and to use existing products more
effectively. One example is topical corticosteroids which in some circumstances may cause
damage to the skin barrier, and in others they may help repair it by inhibiting the production of
secondary proteases.
1. Flohr C et al. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004;114(1):150–8
2. Novak N et al. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol.
2003;112(6 Suppl):S128–39
3. Elias PM et al. Epidermal pathogensis of inflammatory dermatoses. Am J Contact Dermatol
1999;10(3):119–26
4. Vasilopoulos Y et al. Genetic association between an AACC insertion in the 3’UTR of the
stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol
2004;123(1):62–6
5. Ekholm IE et al. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the
desquamation process? J Invest Dermatol 2000;114(1):56–63
6. Egelrud Tet al. The dependence of detergent-induced cell dissociation in non-palmo-plantar
stratum corneum on endogenous proteolysis, J Invest Dermatol 1990; 95(4):456–9
7. Kao JS et al. Short-term glucocorticoid treatment compromises both permeability barrier
homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts
for functional abnormalities. J Invest Dermatol 2003;120:456–64
8. Cork MJ et al. Skin barrier damage: Cause or consequence of atopic dermatitis? Poster
presented at AAD 2005, New Orleans, USA
OC39. What Causes Flares of Atopic Eczema?
SM Langan, HC Williams
Centre of Evidence-based Dermatology, Queen’s Medical Centre, Nottingham
sinead.langan@nottingham.ac.uk
Background: Many factors are quoted as causing flares in atopic eczema but with minimal
objective evidence to support their roles.
Objectives: We sought to systematically search, summarise and critically appraise the
evidence to support the roles of individual ‘‘flare’’ factors in atopic eczema.
Methods: We searched Medline and Embase from 1966 until March 2005 to identify relevant
articles for inclusion in our review. There were no language restrictions. Meta-analysis was
not possible due to differences in study methodology and populations. A descriptive
summary of studies is therefore presented.
Results: Our preliminary data has identified 56 papers directly relevant to this review. 44 of
these studies were experimental in design; 11 double blind placebo controlled food
challenges (DBPCFC), 1 blinded direct exposure study to house dust mite, 13 open oral
challenges, 10 non-blinded exposure studies (chlorine, UV, skin applied food tests, wool), 9
atopy patch studies and 2 inhalation challenges. Direct exposure studies, including
experimental exposure and atopy patch testing to aeroallergens, suggest that house dust
mite may have a significant role. Two inhalation studies have demonstrated that inhalation of
aeroallergens can trigger eczema in participants. There were 12 observational studies: 7
questionnaire studies, 3 cohort studies and 2 anecdotal reports. Two recent observational
studies in particular are highlighted. One inferred an association between stress, damp and
heat and disease flares. The other study has suggested that there may be winter and summer
types of eczema, the former flaring in cold weather and the latter when pollen counts are high.
Conclusions/Implications for practice and research: The relationship between climate and
atopic eczema is not yet entirely clear. No definite conclusion can be drawn regarding other
putative ‘‘flare factors’’. One reason might be that atopic eczema is a complex disease with
flares caused by interactions of several exposures in combination, as opposed to factors
working in isolation. Combined prospective observational and experimental studies are
required to clarify roles of these factors. Knowledge of environmental flare factors, such as
temperature, foods and dust, is important as many are modifiable thereby offering a non-drug
approach to treating atopic eczema.
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OC40. Differences in Percutaneous Absorption in Normal and Atopic Dermatitis Skin in
Relation to Molecular Weight
I. Jakasa, M. M. Verberk, M. Esposito, J. D. Bos, S. Kezic
Coronel Institute for Occupational and Environmental Health and Department of Dermatol-
ogy, Academic Medical Center, University of Amsterdam, the Netherlands
i.jakasa@amc.uva.nl
Molecular weight plays a significant role in the percutaneous penetration of chemicals. Atopic
dermatitis is a chronic inflammatory skin disease associated with cutaneous hyperactivity to
environmental triggers and is characterized by dry skin and increased transepidermal water
loss.
Percutaneous penetration of chemicals and drugs might be higher not only in involved but
also in non-involved skin of atopic dermatitis patients.The objective of this study was to
investigate the differences in percutaneous penetration of polyethylene glycol (PEGs) in
subjects with normal skin barrier and subjects with the history of atopic dermatitis in relation
to the molecular weight. Twenty healthy and twenty subjects with history of atopic dermatitis
were exposed to water solution of PEGs in range of 150–590 Da for 6 hours on the volar
forearm. After the end of exposure the stratum corneum was totally removed by means of
tape stripping and the concentration of PEGs and proteins were determined in each strip.
Using Fick’s second law of diffusion the permeation parameters were determined.
The penetration of all PEGs into the stratum corneum was enhanced in non-involved skin of
atopic dermatitis patients. This suggests that even the non-involved skin in atopic dermatitis
patients has a compromised barrier function.
OC41. N-3/N-6 Polyunsaturated Fatty Acids in a Group of Patients with Recalcitrant
Atopic Dermatitis and the Inﬂuence of Balanced Japanese Traditional Diet
Hiromi Kobayashi1, Daisuke Tsuruta1, Mikam Nanatsue2, Kazuko Hirai2, Masamitsu Ishii1
(1) Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka,
and (2) Department of Health and nutrition, Osaka University Graduate School of Human Life
Sciences, Osaka, Japan
hiromik@med.osaka-cu.ac.jp
Background: There are allergic and non-allergic aspects in the significance of diet. Among
non-allergic influence of diet, n-3/n-6 polyunsaturated fatty acid (PUFA) unbalance has been
pointed out to be related to the increase of atopic diseases. In Japan, adult patients with
severe atopic dermatitis (AD) have been increasing in numbers as traditional diet has
replaced by modern confused diet, in which there are the problems of excess intake of n-6
PUFAs and lack of n-3 PUFAs. We reported successfully treated cases with recalcitrant AD
using diet and Kampo, Japanese traditional medicine (JTM), in addition to conventional
therapy (eCAM 2004:1: 49–62, 145–156) and the existence of various viewpoints on diet (Adv
Exp Med Biol. 2004; 546: 281–96). To clarify one of factors in the meaning of diet, we
examined serum n-3/n-6 PUFAs in comparison with clinical severity during treatment of AD as
a pilot study.
Methods: Subjects were consenting outpatients with recalcitrant AD treated at our clinic. For
the treatment, in addition to the standard therapy, diet instruction was performed. Meats, fat,
oil mainly rich in n-6 PUFAs and sweets were recommended to reduce from the menus.
Patients were instructed to ingest diets mainly consisting of traditional food rich in rice,
vegetables, pulse and seafood rich in n-3 PUFAs as a part of JTM. Serum fatty acids in fasting
sera collected before and during therapy were measured by capillary gas chromatography
after methylation of the serum samples.
Results: Serum fatty acids were examined in 112 patients. As a whole, n-3/n-6 ratio before
treatment was 0.16 which was lower than recommended one, 0.33 for Japanese. Clinical
symptoms improved during treatment and n-3 PUFAs increased with mild rise of n-3/n-6 ratio
to 0.19. In a comparison of severity and n-3/n-6 ratio, no correlation was observed for the
total fatty acid, but in patients with an eicosapentaenoic (20:5 n-3) acid/arachidonic (20:4 n-6)
acid ratio of less than 0.3 before therapy, who comprised 70% of all patients, the severity and
n-3/n-6 ratio were inversely related. Regarding the improvement rate of the symptoms, they
improved as n-3 lipids increased.
Case 1: A 41-year-old man with severe AD who had habitual confused diet showed clinical
improvement after adding balanced diet and Kampo on the standard treatment. His serum n-
3/n-6 ratio changed from 0.103 to 0.184 during 23 months accompanied with SCORAD score
change from 66.2 to 15.1. The amount of topical steroids, tacrolimus ointment and Kampo
remedies used in a month decreased during following 2 years. Case 2: A 28-year-old woman
with recalcitrant AD accompanied with severe pruritus was advised to avoid sweet drinks and
to take more balanced Japanese diet. Her symptoms improved after 4 months treatment and
her serum n-3/n-6 ratio changed from 0.137 to 0.223 with SCORAD change from 60.3 to 3.8.
She reported recurrence followed unbalanced diet and made efforts to keep balanced diet
during next 11 months and the status with SCORAD score 0 continued over 6 months.
Discussion: Not all but in a group of patients with recalcitrant AD, excess intake of n-6 PUFAs
and decrease in n-3 PUFAs ingestion might be an aggravating factor. Balanced traditional
Japanese diet in addition to conventional treatment succeeded to improve their symptoms.
These data showed one of the reasons that such a diet has been helpful in the treatment of
recalcitrant AD from the viewpoint of long-term effects.
P18. Evaluation of the Corticosteroid-Sparing Effect of an Emollient Milk in a Large
Population of Infants Affected by Atopic Dermatitis
Josse M, Mengeaud V, Durosier V, Sibaud V, Grimalt R, Cambazard F
Pierre Fabre Research Institute, Toulouse, France and Depts of Dermatology, St Etienne,
France and Barcelona, Spain
marion.josse@pierre-fabre.com
If emollients are considered as standard therapy in the management of atopic patients (1,2),
their corticosteroid-sparing effect in Atopic Dermatitis (AD) has never been clearly
demonstrated.
The aim of this open label, randomised, multicentric study was to evaluate the
corticosteroid-sparing effect of an emollient milk containing Oat Rhealbas extracts in an
homogenous population, of infants aged less than 1 year old suffering from Atopic Dermatitis
(AD).
Children with mild to severe AD (SCORAD index  20 and  70) were randomised in
two parallel groups: a group with the emollient milk applied twice daily, and a group receiving
no emollient. The use of topical corticoids (class II & III desonide corticoids) was allowed in
the event of inflammatory flare-ups in both groups. The primary end point was measurement
of the amount of topical steroids used (grams) at 3 and 6 weeks. The secondary end point
was clinical rating changes (SCORAD index).
162 children (84 in the group with the emollient milk, and 78 in the group without) were
analysed in ITT. Mean age was 6 months. SCORAD index at baseline was 36 in both groups.
At 3 weeks, the amount of class II (moderate potency) topical corticosteroids was
decreased above 5% (non significant) and the class III (high potency) topical corticosteroids
was significantly decreased above 45% (po0.05) in the group with emollient in comparison to
the group without emollient.
At 6 weeks, the amount of class II (moderate potency) topical corticosteroids was
decreased above 7% (non significant) and the class III (high potency) topical corticosteroids
was significantly decreased above 42% (po0.05) in the group with emollient in comparison to
the group without emollient.
At 3 weeks and at 6 weeks, the SCORAD index was significantly improved (po0.0001) with
no difference between the two groups. At 6 weeks, the SCORAD index was significantly
decreased greater than 54% in both groups. The tolerance of the emollient milk containing
Oat Rhealba
s
extracts was judged good to excellent in 94% of cases.
We demonstrated in an large homogenous population of 162 atopic infants, a significant
reduction of class III (high potency) topical steroids consumption (442%) after 3 weeks and 6
weeks of use of a specific emollient milk containing Oat Rhealba
s
extract. This emollient milk
appears as a safe and corticosteroid-sparing auxiliary treatment in Atopic Dermatitis
management.
1. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury
R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis. J Am
Acad Dermatol. 2004;50:391–404.
2. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on
pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49:1088–95.
P19. Refractory Atopic Dermatitis Associated with Cobalamine Deﬁciency Treated with a
Single B12 Injection
Mohammad Nabavi MD
Dept.of Pediatrics, Division of Allergy & Immunology, Semnan Medical University, Semnan,
Iran mnabavi44@yahoo.com
Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to material
in contact with the skin. It arises some hours after contact with the responsible material, and
settles down over some days providing the skin is no longer in contact with it. Allergic contact
dermatitis is distinct from irritant contact dermatitis, in which a similar skin condition is
caused by excessive contact with irritants. Irritants include water, soaps, detergents,
solvents, acids, alkalis, and friction. Irritant contact dermatitis may affect anyone, providing
they have had enough exposure to the irritant, but those with atopic dermatitis are particularly
sensitive. Most cases of hand dermatitis are due to contact with irritants. The dermatitis is
generally confined to the site of contact with the allergen, although severe cases may extend
outside the contact area or it may become generalised. Sometimes the allergen is transmitted
from the fingers so unexpected sites can be affected (e.g., the eyelids and genitals).
Dermatitis is unlikely to be due to a specific allergen if the area of skin most in contact with
that allergen is unaffected. The affected skin may be red, swollen and blistered or dry and
bumpy. Cobalt is a metal found naturally in soil, dust, and seawater. It is usually found in
association with nickel. Cobalt and its salts have many uses. Reactions to contact with cobalt
in an allergic individual include allergic contact dermatitis and irritant dermatitis. Vitamin B12
injections administered to allergic individuals may produce a red, tender and itchy area
around the site of the injection. Oral ingestion of vitamin B12 is known to cause intractable
hand eczema is some patients. ‘‘Nickle’’ which is the most common cause of allergic contact
dermatitis, is not associated with worsening of dermatitis following administration of Vitamin
B12 and this feature is in contrast with cobalt allergy. In this article, a 21 year girl with nickle
dermatitis will be presented who was refractory to usual treatments held for contact
dermatitis. Following diagnosis of macrocytic anemia and treatment with Vitamin B12
injections, significant improvement in signs and sympthoms occured with no further
recurrence.
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P20. Does Prolonged Topical Application of Tacrolimus in Children Result in Systemic
Accumulation?
Elena Tonin, Barbara Pigozzi and Anna Belloni Fortina
Dermatology Unit, Department of Pediatrics, University of Padua, Italy
belloni@pediatria.unipd.it
Systemic exposure following topical application of tacrolimus is minimal and decreases with
time as the skin condition improves. However most studies have evaluated tacrolimus
concentration in blood following topical application for less than one month.
We have evaluated tacrolimus blood concentration in 34 children (aged 2–14 years, mean
age 7 years) with moderate to severe atopic dermatitis (mean SCORAD index 61.9, range
32.3–87.1) after 3, 6 and 12 months of repeated application of Tacrolimus ointment 0.03%.
The tacrolimus blood concentration was assayed using EMIT (enzyme multiplied immune
assay technique). The lower limit of quantification of this method was 0.25ng/L.
All blood samples assayed were below the lower limit of quantification (ieo0.25ng/L).
Our preliminary data seem to indicate that there is no systemic accumulation of tacrolimus
after repeated application for long periods (  3months).
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